# Adjusting for Selection Bias Due to Missing Eligibility Criteria in Emulated Target Trials

Luke Benz<sup>1</sup>, Rajarshi Mukherjee<sup>1</sup>, Issa Dahabreh<sup>1,2,3</sup>, Rui Wang<sup>1,4,5</sup>, David Arterburn<sup>6</sup>, Heidi Fischer<sup>7</sup>, Catherine Lee<sup>8</sup>, Susan Shortreed<sup>9,10</sup>, and Sebastien Haneuse<sup>1</sup>

<sup>1</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

 $^2\mathrm{CAUSALab},$  Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>3</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>4</sup>Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA

<sup>5</sup>Department of Population Medicine, Harvard Medical School, Boston, MA, USA <sup>6</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

<sup>7</sup>Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA

<sup>8</sup>Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA

<sup>9</sup>Biostatistics Division, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

<sup>10</sup>Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA

June 25, 2024

#### Abstract

Target trial emulation (TTE) is a popular framework for observational studies based on electronic health records (EHR). A key component of this framework is determining the patient population eligible for inclusion in both a target trial of interest and its observational emulation. Missingness in variables that define eligibility criteria, however, presents a major challenge towards determining the eligible population when emulating a target trial with an observational study. In practice, patients with incomplete data are almost always excluded from analysis despite the possibility of selection bias, which can arise when subjects with observed eligibility data are fundamentally different than excluded subjects. Despite this, to the best of our knowledge, very little work has been done to mitigate this concern. In this paper, we propose a novel conceptual framework to address selection bias in TTE studies, tailored towards time-to-event endpoints, and describe estimation and inferential procedures via inverse probability weighting (IPW). Under an EHR-based simulation infrastructure, developed to reflect the complexity of EHR data, we characterize common settings under which missing eligibility data poses the threat of selection bias and investigate the ability of the proposed methods to address it. Finally, using EHR databases from Kaiser Permanente, we demonstrate the use of our method to evaluate the effect of bariatric surgery on microvascular outcomes among a cohort of severely obese patients with Type II diabetes mellitus (T2DM).

### Introduction

Target trial emulation (TTE) has recently gained popularity as a causal inference framework for analyzing electronic health record (EHR) based observational studies. The premise of TTE is that most observational analyses examining comparative effectiveness represent an attempt to answer some causal question. Ideally, such a causal question would be answered by a randomized controlled trial (RCT), the so-called "target trial." Hernán et al. outline a framework for analyzing observational studies while being explicit about the target trial that the analysis seeks to emulate (1). This framework entails explicitly specifying the nature of the target trial through its protocol components (including eligibility criteria and time-zero) and analyzing the observational data in a manner that adheres as closely to the corresponding target trial as possible. Furthermore, TTE offers a principled road map towards thinking about and addressing challenges of observational studies, including confounding (2), immortal-time bias (3, 4), and differential non-adherence/loss to follow-up (5). This analysis framework has been applied to epidemiological applications in the study of coronary heart disease and cardiovascular surgery (6–9), HIV (10–12), cancer (13–17), reproductive health (18–20), COVID-19 (21–25), and others (26–28).

In EHR data, patients may frequently meet the eligibility criteria for inclusion in a study population at many points in time, and determining where to begin follow-up time can be challenging, particularly for non-initiators of treatment. Emulating a target trial using observational data that chooses a single fixed time point and then follows eligible subjects who happened to initiate or not initiate treatment at that time is a valid way to deal with this challenge (3), but would exclude much of the available data. Furthermore, at any fixed point in time, initiation of a particular treatment may be exceedingly rare, making the efficacy or safety of the treatment of interest difficult to analyze due to low power. To address this, many works pursuing TTE have used a sequential variation of this framework when analyzing time-to-event outcomes (6-10, 13, 16, 20, 21, 25, 26). Briefly, a series of target trials are conducted at regularly occurring intervals (e.g. monthly or annually) and pooled together in a much larger data set.




Figure 1: Overview of the sequential target trial emulation design. At regular time intervals, subjects are classified initiators of an exposure during that interval or non-initiators. Eligible subjects are ascertained to comprise an analysis data set for each target trial. While each trial could be analyzed individually, data are commonly pooled across trials into a single analysis dataset.

As illustrated in Figure 1, determining which subjects meet eligibility criteria for inclusion in the study population is a critical step. Because EHR data are created for clinical and billing purposes,

not all covariates relevant to the research question of interest are routinely collected in clinical care, and such information may not be collected consistently across time (29). Therefore, missing data in variables that define study eligibility criteria presents an important challenge. In practice, patients with incomplete eligibility data are frequently excluded from analysis (7) despite the possibility of selection bias. Alternatively, eligibility status may be imputed via a patient's most recent covariate value(s) (30), even though such value(s) may not correctly reflect a patient's current eligibility status (Figure 2).

Despite the popularity of the target trial framework, very few works have considered the problem of selection bias due to missing eligibility criteria (31). Tompsett et al. proposed multiple imputation of eligibility-defining criteria and demonstrated its utility in addressing selection bias (31). In contrast to the work of Tompsett et al., which focuses on a single target trial and continuous outcome, we focus on time-to-event endpoints under a sequence of target trials and the added complexities that are introduced in this setting. In this work, we outline an inverse probability weighting (IPW) framework to address selection bias in TTE studies tailored towards time-to-event endpoints. Selection bias due to missing eligibility criteria can be a concern for a substantial number of published observational studies in comparative effectiveness, and as such, this work aims to fill an important gap in the literature.

### **Bariatric Surgery**

This work is motivated by a series of EHR-based observational studies to understand long-term outcomes following bariatric surgery (30, 32-38). To illustrate the complexity of typical EHR data, and thus, potential challenges in determining eligibility when emulating a target trial, Figure 2 depicts EHR-derived information for six non-surgical subjects from DURABLE, an NIH funded study examining long-term outcomes of bariartic surgery (30, 33-35, 39) using EHR data across three large health care organizations in the Kaiser Permanente system.

In each panel, information on hemoglobin A1c (A1c, blue dots) and body mass index (BMI, red dots) are plotted on the respective dates each measurement was recorded. BMI values are shown in relation to a cutoff of 35 kg/m<sup>2</sup>, the typical clinical cutoff for consideration of bariatric surgery at Kaiser Permanente (40), while A1c values are shown in relation to cutoffs of 5.7% (prediabetes) and 6.5% (diabetes) (41, 42). Both BMI and A1c are important in ascertaining study eligibility when emulating hypothetical target trials (30). In simulations, for example, we consider two such studies of the effect of bariatric surgery on microvascular outcomes, the first of which has an eligibility criteria consisting of BMI ( $\geq 35 \text{ kg/m}^2$ ) and A1c ( $\geq 5.7\%$ ) cutoffs, while the latter only requires a BMI exceeding  $\geq 35 \text{ kg/m}^2$ . Our data application studies the same question in a population of individuals with diabetes and who have a BMI above 35 kg/m<sup>2</sup>, where both measures are necessary for determining the eligible study population.

Crucially, while some patients in Figure 2 have rich data on both BMI and A1c (e.g. patients 1 and 4), others have rich information on BMI (e.g. 2, 3, and 5) or A1c only (e.g. patient 6). Furthermore, some have long gaps between measures of a certain type (e.g. patients 2, 3, 6) despite getting frequent measures of another type. Additionally, patients may frequently change which side of one of these clinically relevant cutoffs they belong to, and thus so too would their eligibility for inclusion in a particular study using one or more of these cutoffs as inclusion criteria.




Figure 2: Hemoglobin A1c (HbA1c, blue dots) and body mass index (BMI, red dots) measurements over time for six non-surgical patients in the DURABLE study. Measurements are shown in relation to a clinically relevant BMI threshold for consideration of bariatric surgery (35 kg/m<sup>2</sup>), as well as A1c cutoffs defining prediabetes (5.7%) and diabetes (6.5%).

# Notation and Problem Set Up

### **Estimands of Interest**

Suppose interest lies in understanding the comparative effectiveness of some binary treatment on a time-to-event outcome, using data from an EHR database. Due to the rarity of subjects initiating exposure at any particular point in time, as is the case with bariatric surgery (32), suppose that a sequence of trials are run and subsequently pooled together for analysis.

To formalize this, let  $m \in \{1, ..., M\}$  index a series of trials across M regularly occurring intervals (e.g. months). Define  $E_{mk} \in \{0, 1\}$  to be a binary indicator denoting whether subject k satisfies the eligibility criteria for inclusion in the study at baseline of trial m. Subjects may meet the study eligibility criteria at many points in time, and thus may be included in multiple trials. Let  $A_{mk} \in \{0, 1\}$  denote the treatment status at baseline of trial m for subject k, and  $T_{mk} = \min(T_{mk}^*, T_{mk}^C)$  be the observed event time for subject k in trial m, which is the minimum of some true event time  $T_{mk}^*$ and a censoring time  $T_{mk}^C$ . Following Hernan et al. (3, 6, 43), we re-express outcomes on a discrete time scale as follows:

$$\mathbf{Y}_{mk} = \begin{pmatrix} Y_{mk1} \\ Y_{mk2} \\ \vdots \\ Y_{mkT_{mk}} \end{pmatrix} \text{ where } Y_{mkt} = \begin{cases} 1 & T_{mk}^* \le t \\ 0 & T_{mk}^* > t \end{cases}$$

As will become clear, doing so enables the use of time-varying IPW to control for a variety of potential biases that cannot be easily addressed in continuous time (43).

Additionally, throughout, we let over bars denote variable history. For example,  $\overline{Y}_{mkt} = 0$  indicates that a subject has not experienced the outcome of interest through the end of the  $t^{\text{th}}$  interval since baseline of trial m. Analogously, we denote treatment status for subject k at time t of trial m as  $A_{mkt}$ , and treatment history  $\overline{A}_{mkt}$ , with  $\overline{A}_{mkt} = a \mathbb{1}_t$  denoting a constant treatment history of a for all t previous time periods.. Unlike when referencing outcome history, the subscript t in exposure history (and later, covariate history) denotes the start of the  $t^{\text{th}}$  interval. Finally, we let  $Y_{mkt}^{(\bar{a})}$  denote counterfactual discrete survival indicators under treatment history  $\overline{A}_{mkt} = \overline{a}$ .

Possible estimands of interest are established using pooled logistic regression (5, 43, 44), typically with the goal of estimating a common effect across all time periods.

$$\operatorname{logit}\left[P(Y_{mk(t+1)}^{(\bar{a})} = 1 | E_{mk} = 1, \overline{Y}_{mkt}^{(\bar{a})} = 0, \overline{A}_{mk(t+1)} = a \mathbb{1}_{(t+1)})\right] = \psi_{0,t}^{(m)} + \psi a \tag{1}$$

In Equation 1,  $\psi$  represents the observational analogue of an per-protocol (PP) effect, with sustained adherence to baseline treatment strategy  $A_{mkt} = A_{mk} = a$  for  $0 \leq t \leq T_{mk}$ . Interest could also lie in the observational analogue of an intention-to-treat (ITT) effect, that is the effect of recommendation to undergo treatment without requiring subsequent adherence. In practice, it is difficult to extract information from EHR data on treatment recommendations (i.e. doctor's suggestion to start or discontinuine treatment) and as such, an ITT analogue might be proxied by replacing  $\overline{A}_{mk(t+1)} = a \mathbb{1}_{(t+1)}$  in Equation 1 with  $A_{mk} = a$ , thereby considering the effect of baseline treatment status only (1). While such an estimand may be better referred to as a weak per-protocol effect, in contrast to the strong per-protocol effect of  $A_{mkt} = A_{mk} = a$  for all t, we refer to it as an intention-to-treat effect as is typical in related literature (3, 6–8, 14, 18, 19, 27).

Notions of adherence in the context of our motivating bariatric surgery example are somewhat different than in other applications, where patients may switch or stop treatment, perhaps due to adverse effects or clinician recommendations. As patients can be eligible for inclusion in multiple trials, non-surgical controls may be included in trial  $m_1$  under treatment status  $A_{m_1k} = 0$  and later undergo bariatric surgery and enter trial  $m_2 > m_1$  with treatment status  $A_{m_2k} = 1$ . For such patients, treatment status at this later time is inconsistent with treatment at baseline of the earlier trial, and in this sense, from the perspective of trial  $m_1$ , all subsequent person-time these subjects contribute in this earlier trial is non-adherent to their original treatment status. While this technical distinction between per-protocol and intention-to-treat effects for bariatric surgery may be clinically less meaningful than in other applications, as patients cannot stop or switch treatment after undergoing surgery, we keep this terminology for consistency with how such estimands are referenced in the literature on TTE (3, 6–8, 14, 18, 19, 27). Furthermore, we compute both estimands to illustrate use of this general framework which can be used in numerous EHR-based applications, including those where distinctions between per-protocol and ITT effects are clinically more meaningful.

Under the marginal structural model in Equation 1,  $\psi$  denotes a causal log-odds ratio, which can be viewed as discrete hazard ratio (on the log scale) when prevalence of the outcome in any within any given time period is small (14, 43–45).  $\psi_{0,t}^{(m)}$  is analogous to a baseline hazard at time t, which can vary by trial m. An alternative choice would be to estimate a shared baseline hazard across trials,  $\psi_{0,t}$ , but this may not be appropriate when the time period spanning all trials is large. Thus, while the baseline hazard is relative to time t = 0 (baseline) within each trial, this set-up allows for some form of heterogeneity across trials.

Critical to the definition of this model is the time-varying eligibility indicator  $E_{mk}$ , which is straightforward to regularly ascertain for some patients and impossible for other subjects (Figure 2). There are a number of ways in which missing eligibility criteria could arise and potentially result in bias. Figure 3 highlights three such ways which are explored in greater detail in subsequent simulation studies.

Finally, let  $R_{mk}$  be a complete case indicator, that is whether individual k's eligibility status can be ascertained at baseline of trial m. When subjects whose eligibility can not be ascertained are dropped from analysis, the estimands that standard methods will target implicitly change, specifically to:

$$\operatorname{logit}\left[P(Y_{mk(t+1)}^{(\bar{a})} = 1 | E_{mk} = 1, R_{mk} = 1, \overline{Y}_{mkt}^{(\bar{a})} = 0, \overline{A}_{mkt} = a \mathbb{1}_{(t+1)})\right] = \theta_{0,t}^{(m)} + \theta a$$
(2)

Selection bias occurs when  $\theta \neq \psi$ , that is, when the treatment effect among eligible complete cases does not equal the treatment effect among the entire eligible population. Note that the term selection bias is sometimes an umbrella term in the epidemiology literature and in related fields. For example, in Figure 3, selection bias is used to describe bias which arises both from conditioning on a collider and dropping subjects from the population of interest when there is effect modification. While it's worth distinguishing that there are more than one way in which bias can arise from dropping subjects with incomplete eligibility criteria, our solution to all such sources of bias will the same, and as such in the remainder of the paper we simply refer to such biases as selection bias (5).

#### Notation for Additional Sources of Bias

Selection bias is not the only potential source of bias in observational studies, and other common sources of bias, including confounding and differential censoring/non-adherence, require additional notation. Despite the fact that treatment status  $A_{mkt}$  may change over time, from the perspective of each baseline of each trial m, we are only interested in treatment status as a point exposure, and thus time-varying confounding is not a concern (though baseline confounding remains a concern) (45).

Define  $C_{mkt}$  to be a binary indicator denoting that subject k was censored during time period t of trial m (that is  $T_{mk}^C \in [t, t+1)$ ), and let  $N_{mkt}$  represent a non-adherence indicator  $\mathbb{1}(A_{mk} \neq A_{mkt})$ , denoting whether at time t of trial m, subject k has switched treatment from baseline (of trial m).  $\overline{N}_{mkt} = 0$  and  $\overline{C}_{mkt} = 0$  indicate that subject k has remained adherent to baseline treatment status and uncensored, respectively, through the start of interval t of trial m.

Covariates will be necessary to address both selection bias and other sources of potential bias. We let  $L_{mk}$  be a vector of covariates at baseline of trial m,  $L_{mkt}$  a vector of covariates at the beginning of interval t of trial m, and  $\overline{L}_{mkt}$  covariate history.

### Methods

#### **Inverse Probability Weighting Framework**

To address missing data in eligibility defining criteria, let baseline covariates  $L_{mk} = (L_{mk}^e, L_{mk}^c)$ where  $L_{mk}^e$  are the covariates which define eligibility for inclusion in trial m and  $L_{mk}^c$  are all other baseline covariates. That is,  $E_{mk} = g(L_{mk}^e)$  where  $g(\cdot)$  is a deterministic eligibility defining rule. In previously conducted observational studies examining the long-term outcomes following bariatric surgery, eligibility rules have been functions of both A1c and/or BMI (30, 33, 34, 39, 46, 47); we replicate this complex eligibility criteria in our simulations studies.

In the presence of missing eligibility data, we proceed by making the following novel eligibility missing at random (MAR) assumption:

$$R_{mk} \perp \!\!\!\perp E_{mk} \mid \overline{\boldsymbol{L}}_{mk}^c, \overline{A}_{mk}, C_{mk} = 0 \tag{3}$$

This MAR assumption states that whether or not a subject's eligibility status can be ascertained is independent of the value of their eligibility status, given histories for treatment and non-eligibility defining covariates. Utilizing Equation 3, we propose weights for addressing potential selection bias due to the restriction of analysis to subjects with complete data.

$$W_{mk}^{R} = P(R_{mk} = 1 \mid \overline{L}_{mk}^{c}, \overline{A}_{mk}, C_{mk} = 0)^{-1}$$
(4)

Even in the absence of missing eligibility data, care must be taken not to attribute differences in observed outcomes to differences in treatment status without accounting for the fact that treated subjects may be fundamentally different than unexposed subjects. In particular, confounding, differential loss to follow-up, and differential non-adherence must all be addressed in ways that allow rigorous comparison of these observed outcomes. IPW has previously been used in this analytical framework to address confounding and differential censoring, typically not distinguishing between loss to follow-up and non-adherence (6, 7, 10, 14, 15, 48, 49). Inverse probability weights which addresses these problems are as follows:

$$W_{mk}^{A} = P(A_{mk} \mid \boldsymbol{L}_{mk}, E_{mk} = 1)^{-1}$$

$$W_{mkt}^{C} = \prod_{i=0}^{t} P(C_{mki} = 0 \mid \overline{C}_{mk(i-1)} = 0, \overline{N}_{mk(i-1)} = 0, \boldsymbol{L}_{mki}, E_{mk} = 1, A_{mk})^{-1}$$

$$W_{mkt}^{N} = \prod_{i=0}^{t} P(N_{mki} = 0 \mid \overline{C}_{mk(i-1)} = 0, \overline{N}_{mk(i-1)} = 0, \boldsymbol{L}_{mki}, E_{mk} = 1, A_{mk})^{-1}$$
(5)

Working with observed data among subjects with ascertainable eligibility status amounts to fitting the following pooled logistic regression model:

$$\log t \left[ P(Y_{mk(t+1)} = 1 | E_{mk} = 1, R_{mk} = 1, \overline{Y}_{mkt} = 0, A_{mk}, \overline{N}_{mkt} = 0, \overline{C}_{mkt} = 0) \right] = \tilde{\theta}_{0,t}^{(m)} + \tilde{\theta} A_{mk}$$
(6)

Fitting the model in Equation 6 with weights

$$W_{mkt} = W_{mk}^A \times W_{mkt}^C \times W_{mkt}^N \times W_{mk}^R \tag{7}$$

recovers the parameter of interest  $\psi$  when component weight models are correctly specified. Namely, weights  $W_{mk}^A \times W_{mkt}^C \times W_{mkt}^N$  create a psuedo-population in which both treatment decisions and censoring are independent of covariates which may differ by treatment status (e.g.  $\tilde{\theta}$  recovers  $\theta$ ) (2, 5, 7, 10, 14, 45, 49). Similarly, weights  $W_{mk}^R$  create a psuedo-population where eligibility status is independent of eligibility ascertainment (e.g.  $\theta$  recovers  $\psi$ ). Assumptions required for recovery of  $\psi$  utilizing these inverse probability weights are discussed in the Supplementary Materials.

Without loss of generality, the model in Equation 6 targets a per-protocol effect. Analysts choosing to pursue intention-to-treat effects could drop adherence  $(\overline{N}_{mkt} = 0)$  from the model. In other settings, differential loss to follow-up may not be of concern. In either of these cases, Equation 7 can easily be modified to exclude irrelevant weights. Table 1 summarizes component inverse probability weights, as well as their stabilized analogues, SW (2, 10, 48, 49).

In the remainder of the paper, we let  $\psi_{PP}$  and  $\psi_{ITT}$  denote estimates of observational analogues of per-protocol ( $\psi_{PP}$ ) and ITT effects ( $\psi_{ITT}$ ), respectively, from fitting the model in Equation 6 with appropriate inverse probability weights.

# Simulation Studies

In order to characterize realistic EHR-based settings under which missing eligibility data presents the possibility of selection bias and when it doesn't, and understand the finite sample performance of our proposed method, we developed a series of simulation studies. These simulations (sometimes known as plasmode simulations (50)) are closely tied to data used to study bariatric surgery in DURABLE studies (33–35, 39, 51), and EHR data more generally. Briefly, the DURABLE database was used to both sample covariate vectors  $L_{mk}^c$  and estimate/inform simulation parameters for treatment, outcome, and time-varying eligibility models. Simulated treatments, outcomes, and eligibility statuses were then generated from these models and the covariates sampled. The complete EHR-based simulation infrastructure is described in detail in the Supplementary Materials.

Our simulations evaluated the performance of various analytical approaches under three missing data mechanisms for two different sets of eligibility criteria, one based on BMI ( $\geq 35 \text{ kg/m}^2$ ) and A1c ( $\geq 5.7\%$ ) cutoffs ("hypothetical study #1"), and one based only on the BMI cutoff ("hypothetical study #2"). Due to the identical nature of eligibility for bariatric surgery and inclusion criteria for the second hypothetical study, eligibility ascertainment in this study was only an issue in the non-surgical arm. In both hypothetical studies, interest lay in the per-protocol effect of bariatric surgery on vascular disease outcomes (30, 39).

#### Missing Data Mechanisms




Figure 3: Directed acyclic graphs (DAG) outlining missing data mechanisms used in simulations. Bold lines connecting nodes indicate relationships specified in the simulation study. Dashed lines indicate relationship pairs which could introduce confounding. While simulations did not introduce confounding, the dashed lines show that confounding can exist and be adjusted for without violation of missing at random assumption (Equation 3). Finally, purple lines denote paths along which selection bias is introduced. For simplicity, each DAG represents a single time point t. Figure A demonstrates M-bias, also referred to as collider bias, whereby one conditions on a common effect (R) of a cause of treatment ( $L^{RA}$ ) and a cause of outcome ( $L^{RY}$ ). Figure B extends this structure to include treatment effect heterogeneity in the form of an interaction between A and some component(s) of  $L^{RY}$ . Finally, Figure C considers a more complex type of M-bias where  $L^{RY}$  is not directly associated with outcome but instead is associated with a mediator M through which treatment A is associated with outcome Y. In the context of these simulations, where interest lies in vascular outcomes, examples of such mediators are BMI and A1c values, whose respective frequency of observation is highly heterogeneous.

We utilized three mechanisms for generating missing eligibility criteria, outlined in Figure 3. Let  $L^c = (L^{AY}, L^{RA}, L^{RY})$  where  $L^{AY}$  denotes traditional confounders (i.e. covariates associated with both treatment and outcome),  $L^{RA}$  denotes covariates associated with both eligibility ascertainment (R), and treatment, and  $L^{RY}$  denotes covariates associated with both eligibility ascertainment and outcome. In practice, these sets of variables are unlikely to be disjoint, especially in EHR-based settings where certain covariates are likely associated with eligibility ascertainment, treatment and outcome simultaneously. Nevertheless, we find it useful to make this distinction explicit to demonstrate distinct ways in which selection bias may manifest itself in this setting in the absence of confounding, a challenge for which extensive literature exists (2, 43, 48, 52–56). Paths by which confounding could exist are represented by dotted arrows in Figure 3.

#### Results

Results from hypothetical study # 1 are shown in Table 2 and results from hypothetical study # 2 are shown in Table 3. In all scenarios, estimation of  $\psi_{PP}$  without inverse probability of selection weights resulted in bias ranging from 7-185%. Correct specification of  $W_{mk}^R$  recovered unbiased estimation. In fact, in most settings, incorrect specification of  $W_{mk}^R$  via omission of  $L^{RA}$  still performed reasonably well, suggesting that the association between selection and outcome may drive selection bias more than the association between selection and treatment.

In the second study, when eligibility ascertainment was an asymmetric problem, correct weight specification required estimating separate selection bias weights for those who were treated and untreated. Fitting a single weight model to all subject-trials regardless of treatment status, even one with the correct functional form within the untreated arm, introduced significant bias in  $\hat{\psi}_{PP}$ . This is likely because in hypothetical study # 2, true weights  $W_{mk}^R = 1$  for treated individuals and incorrectly including such subjects when fitting a single selection bias weight model biased estimation of weights for all individuals. Altogether, this suggests that if patterns of eligibility ascertainment are believed to differ substantially between treatment arms, a single parametric model may be insufficient for capturing how  $R_{mk}$  depends on  $\bar{L}_{mk}^c$  and  $\bar{A}_{mk}$  when modeling selection bias weights  $W_{mk}^R$ .

# **Data Application**

To illustrate an application of our IPW framework, with a particular focus on how researchers might think about missing eligibility data in a real EHR example, we studied the long term effect of bariatric surgery on microvascular outcomes, a composite outcome consisting of nephropathy, nephropathy, and retinopathy, among patients with Type 2 diabetes mellitus (T2DM) using a sequential target trial design. Using the DURABLE database, O'Brien and colleagues previously examined this question under a matched cohort design (30). In this previous work, the authors used data up to two years prior to index date (e.g. the date of surgery for the surgical case in each matched group) to ascertain eligibility, excluding patients whose eligibility status could not be determined due to missing data. Determining how far to look back when attempting to ascertain eligibility can be viewed as a bias-variance trade off, whereby longer lookback windows will enable ascertainment of more subjects' eligibility status, but some subjects will be deemed eligible or ineligible incorrectly. The decision to look back two years isn't necessarily right or wrong, but is a distinct choice made by the authors, whose influence on results we explored.

#### **Overview of Data**

Following O'Brien et al. (30), analysis was restricted to patients with diabetes eligible for bariatric surgery between January 1, 2005 and December 31, 2011, with follow-up allowed until September 30, 2015. Under the sequential target trial design, this yielded M = 84 trials, beginning at the start of each month between January 1, 2005 and December 31, 2011.

Specifically, eligibility criteria consisted of a BMI  $\geq 35 \text{ kg/m}^2$  and diagnosis of T2DM. Using a similar definition to that of O'Brien et al., T2DM was defined as having the most recent A1c measurement  $\geq 6.5\%$  or fasting blood glucose measurement  $\geq 126 \text{ mg/dL}$ , within a pre-specified lookback period before the start of trial m, or by having an active prescription for a diabetes medication when trial m began. Exclusion criteria removed patients who had previously undergone bariatric surgery, had a history of microvascular disease, or had been pregnant in the previous 12 months. The endpoint of interest was time to incident microvascular disease (e.g. the first instance of nephropathy, nephropathy, or retinopathy). Patients were censored at the time of death, disenrollment from their health plan, cancer, following a period of 13 months without weight or blood pressure measurements, or end of study (30).

#### Ascertainment of Eligibility




Figure 4: Joint distribution of eligibility and ascertainment status  $(E_{mk}, R_{mk})$  across nearly 44 million subjecttrials. In general, allowing longer lookback times before the start of trial *m* increases the number of subjects for whom eligibility can be ascertained  $(R_{mk} = 1)$ . However, measurement values from longer lookbacks may less accurately reflect a subjects' eligibility defining covariates (as in Figure 2). Essentially, the choice of lookback windows can be framed as a sort of bias-variance trade off.

After filtering the data to exclude subject-trials where patients had a history of microvascular complications or were censored for one of the reasons mentioned above, 43,805,050 subject-trials across K = 1, 152, 227 subjects remained for which eligibility needed to be assessed. To study the sensitivity of results to the length of time used to establish study eligibility, we used a grid of lookback times. BMI was assessed using the most recent value within  $\{1, 3, 6, 12\}$  months before the start of trial m and TD2M status was assessed using the most recent blood glucose lab measurements available with  $\{1, 3, 6, 12, 18, 24\}$  months.

If measurements were unavailable for either of the two eligibility criteria, eligibility status was deemed missing  $(R_{mk} = 0)$ . The distribution of eligibility status is shown in Figure 4. Under the shortest lookback windows, eligibility could not be ascertained for over 80% of subject-trials. Increasing lookback windows for both BMI and A1c increased the number of subjects for whom eligibility could be ascertained, though the number of subject trials with confirmed eligibility ( $E_{mk} = 1$ ,  $R_{mk} = 1$ ) tended to plateau around the 12 month blood glucose lookback window.

#### Sensitivity of Effect Estimates to Eligibility Lookback Times

ITT and per-protocol effect estimates for bariatric surgery on each individual outcome of interest, as well as the composite, are shown in Figure 5. Accounting for confounding through the inclusion of  $W^A$  attenuated effect estimates towards the null. Notably, accounting for the possibility of selection bias through inclusion of  $W^R$  also attenuated effect estimates, albeit to a lesser extent.

Such findings are consistent with discussion of missing data by O'Brien and colleagues, who noted that subjects dropped for missing data were more likely to have had shorter duration of observed diabetes than subjects retained with complete data (30). One possible explanation for the smaller degree of attenuation following adjustment for selection bias than for confounding/non-adherence alone is that the covariates used to adjust for selection bias were a strict subset of the covariates used to address confounding/non-adherence. This need not be the case in all studies however.

While it may not qualitatively change the fact that bariatric surgery is associated with long term decrease in risk of microvascular complications, failure to account for the possibility of selection bias due to missing eligibility data may lead one to overstate effect sizes by up to 10%. In general, effect estimates were somewhat sensitive to choices of lookback times for both BMI and blood glucose lab measurements particularly for individual component outcomes. In some cases, differences between effect estimates using the longest and shortest lookback windows were on par with differences between estimates accounting and failing to account for selection bias.

#### **Final Results**

We picked a BMI lookback window of 3 months and a blood glucose lookback window of 12 months for which to report full 95% confidence intervals using B = 1,000 bootstrap replicates resampled at the subject (k) level. Confidence intervals were computed using a Normal approximation interval rather than a percentile-based interval method (57, 58) due to the limit of replicates that is computationally feasible on such a large dataset (24, 25). Inferential procedures for our IPW framework, including coverage properties of various bootstrap techniques, are discussed in the Supplementary Materials.

Effect estimates from Table 4 are not directly comparable to results reported by O'Brien and colleagues, who estimate time-varying hazard ratios HR(t) as opposed to a common hazard ratio which we report (30). Nevertheless, results between our work and O'Brien et al. are qualitatively very similar, with estimates reported in this work perhaps slightly attenuated compared to what one might reasonably posit a common hazard ratio estimated by O'Brien et al. would be based on averaging HR(t) over various reported time points.

Despite utilizing a product of inverse probability weights, which are known to increase variance of associated estimators (2, 59), efficiency of out reported estimates met or exceeded that reported by O'Brien et al. at any time point. This likely owes to the fact that our choice of design did not utilize matching, thereby retaining a much greater percentage non-surgical patients than the matched cohort design used by O'Brien and coauthors.




Figure 5: Intention-to-treat and per-protocol discrete hazard ratio estimates for the effect of bariatric surgery on microvascular outcomes. Eligibility  $(E_{mk})$  was assessed over a grid of lookback windows before the start of trials m for both blood glucose and BMI measurements. Estimates are reported using various combinations of inverse probability weights. Note that Y-axis scales differ between component outcomes in order to highlight differences between various weight combinations, which frequently are smaller than those across component outcomes.

### Discussion

The target trial emulation framework of Hernán and Robbins (1) has exploded in popularity in recent years and been lauded for laying out a road map which enables, or even forces researchers to think critically about complex design aspects through which bias may enter their study. Unfortunately, missing data, particularly missing data in eligibility defining criteria, is not part of this road map. In this work, we demonstrated that improper handling of missing eligibility data posed the threat of selection bias across a range of common scenarios in EHR-based observational studies, in hopes of demonstrating that consideration of missing eligibility data should be part of this road map going forward.

Crucial to both thinking about and accounting for missing eligibility criteria is the missing at random assumption postulated in Equation 3. At its core, this MAR assumption states that whether or not one's eligibility status can be ascertained is independent of what that eligibility status is, after accounting for everything observable for all patients. As is typical of MAR assumptions, this MAR assumption is not testable in practice. Common violations of this assumption are likely to be found in cases where study eligibility criteria can be viewed as some notion of patient health not captured by covariates included in the analysis, with a patient's health driving how frequently they're followed in the EHR.

When analysts feel this MAR assumption is violated, alternative MAR assumptions can be conceived. For example, one could additionally condition on things like eligibility history (both status E and eligibility defining covariates  $L^e$ ). This relaxed assumption may be more likely to hold at the expense of presenting analysts with non-monotone missingness, something much harder to rectify. While violations of this MAR assumption are not ideal, violations where subjects with missing eligibility data were less likely to have been eligible seem somewhat less harmful than the other direction, where subjects without eligibility defining covariates were more likely to have been eligible.

We noted that one possible explanation why adjusting for selection bias only attenuated effect estimates toward the null by a small amount in our data application was that the set of variables used to adjust for these two sources of bias were very similar. While the focus of this work was on marginal effect estimates, such an observation leads us to hypothesize that the possibility of selection bias may not be as bad if conditional effect estimates are of primary interest and the set of covariates associated with selection, treatment, and outcome are similar. Nevertheless, one still needs to consider the possibility of selection bias in this setting as, Tompsett et al. showed that selection bias was still a concern when one estimated marginal effects by averaging over conditional effect estimates under a linear regression model (31).

Tompsett et al. discussed a notion of MAR related to eligibility criteria but never provided a formal statement of what a MAR assumption would look like in their framework. In contrast to an IPW approach, Tompsett et al. proposed multiple imputation of eligibility defining criteria, something they demonstrated can also address selection bias. This approach may not be feasible in some EHR-based observational studies, particularly when a sequence of target trials are pooled together. For example, if we had attempted to apply multiple imputation in our data application, we'd be attempting to impute eligibility status for 50-85% of subject trials (Figure 4). In their supplementary materials, Tompsett and colleagues note inverse probability weighted outcome regressions as an alternative solution, but found limited improvement for this estimator compared to unweighted outcome regressions. Combinations of inverse probability weighting and imputation have been used to address missing data in other contexts (60, 61), and may offer a flexible path forward for dealing with non-monotone missingness in eligibility defining covariates as well as simultaneous missingness in other variables such as confounders or outcomes. We pursued an IPW approach for several reasons. To begin with, it's a natural choice given that other concerns are already commonly addressed using IPW, so inclusion of additional weights fits seamlessly into existing analysis pipelines. Furthermore, addressing missing data with IPW allows resulting models to recover whatever effect estimates they would target under complete data (62). Finally, notions of multiply robust estimators (63) for addressing confounding, censoring, and non-adherence are not typically utilized in TTE studies even when missing eligibility data is not a concern (23, 28), so addressing these challenges plus missing data in a more robust manner than IPW seems both substantially more difficult and incongruent to methods used in practice.

Though this work focused on sequential target trial emulation, its ideas are transferable to other study designs, as one of the first steps in any observational study is determining the eligible study population. The matched cohort design is one that has been used extensively in the study of long term outcomes following bariatric surgery (30, 33–36, 38, 39, 64), so that design may be immediate interest, though challenges could arise when eligibility defining covariates are also used to match treated and untreated subjects.

Finally, a reasonable critique of this work is the need to get multiple weight models correctly specified to obtain consistent estimation of effects of interest. Analysts may be able to get reasonably close to correct models but are likely to misspecify some or all weight models in practice. Thus, a goal of future work is to look towards semi-parametric theory (65–67) with the goal of establishing robust and efficient estimators which perform well even under some degree of model misspecification.

# Code Availability

All code for analysis and simulations is made available on GitHub at https://github.com/lbenz730/missing\_eligibility\_tte.

# Funding

This work was supported by NIH Grant R01 DK128150-01 (LB, RM, RW, DA, CL, HF, SS, SH).

# References

- [1] Hernán Miguel, Robins James. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available American Journal of Epidemiology. 2016;183:758-764.
- [2] Hernán MA, Robins J. Causal Inference: What if. Boca Raton: Chapman & Hall/CRC 2024.
- [3] Hernán Miguel A, Sauer Brian C, Hernández-Díaz Sonia, Platt Robert, Shrier Ian. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses *Journal of Clinical Epidemiology*. 2016;79:70-75.
- [4] Agarwal Parul, Moshier Erin, Ru Meng, et al. Immortal Time Bias in Observational Studies of Time-to-Event Outcomes Cancer Control. 2019;25:417-424.
- [5] Hernán Miguel A., Hernández-Díaz Sonia, Robins James M. A Structural Approach to Selection Bias *Epidemiology (Cambridge, Mass.)*. 2004;15:615–625.
- [6] Hernán Miguel, Alonso Alvaro, Logan Roger, et al. Observational Studies Analyzed Like Randomized Experiments An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease *Epidemiology*. 2008;19:766-79.
- [7] Danaei Goodarz, Rodríguez Luis A, Cantero Ofelia F, Logan Roger, Hernán Miguel A. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease *Statistical methods in medical research*. 2013;22:70–96.
- [8] Danaei Goodarz, García Rodríguez Luis A, Cantero OF, Logan Roger W, Hernán Miguel A. Electronic medical records can be used to emulate target trials of sustained treatment strategies *Journal of Clinical Epidemiology*. 2018;96:12–22.
- [9] Massol Julien, Simon-Tillaux Nathalie, Tohme Joelle, et al. Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data *Critical Care.* 2023;27.
- [10] Cain Lauren E., Robins James M., Lanoy Emilie, Logan Roger, Costagliola Dominique, Hernán Miguel A.. When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data International Journal of Biostatistics. 2010;6:Article 18.
- [11] Gran Jon Michael, Røysland Kjetil, Wolbers Marcel, et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study *Statistics in Medicine*. 2010;29:2757–2768.
- [12] Caniglia Ellen C, Robins James M, Cain Lauren E, others . Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals *Statistics* in Medicine. 2019;38:2428–2446.
- [13] Emilsson Louise, García-Albéniz Xabier, Logan Roger W, Caniglia Ellen C, Kalager Mette, Hernán Miguel A. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer JAMA Oncology. 2018;4:63–70.
- [14] Dickerman Barbra A., García-Albéniz Xabier, Logan Roger W., al. Avoidable Flaws in Observational Analyses: An Application to Statins and Cancer Nature Medicine. 2019;25:1601–1606.

- [15] Petito Lucia C., others . Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database JAMA Network Open. 2020;3:e200452-e200452.
- [16] Maringe Camille, Benitez Majano Sara, Exarchakou Athena, et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data *International Journal of Epidemiology*. 2020;49:1719–1729.
- [17] Kwee S. A., Wong L. L., Ludema C., et al. Target Trial Emulation: A Design Tool for Cancer Clinical Trials JCO Clinical Cancer Informatics. 2023;7:e2200140.
- [18] Yland Jennifer J., Chiu Yu-Han, Rinaudo Paolo, Hsu John, Hernán Miguel A., Hernández-Díaz Sonia. Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction *Human Reproduction*. 2022;37:793–805.
- [19] Chiu Yu-Han, Yland Jennifer J., Rinaudo Paolo, et al. Effectiveness and safety of intrauterine insemination vs. assisted reproductive technology: emulating a target trial using an observational database of administrative claims *Fertility and Sterility*. 2022;117:981–991.
- [20] Caniglia Ellen C, Zash Rebecca, Fennell Catherine, others . Emulating Target Trials to Avoid Immortal Time Bias - An Application to Antibiotic Initiation and Preterm Delivery *Epidemi*ology. 2023;34:430–438.
- [21] Gupta Shruti, others . Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 JAMA Internal Medicine. 2021;181:41-51.
- [22] Barda Noam, Dagan Noa, Cohen Cyrille, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study *The Lancet.* 2021;398:2093-2100.
- [23] Hoffman Katherine L., Schenck Edward J., Satlin Michael J., others . Comparison of a Target Trial Emulation Framework vs Cox Regression to Estimate the Association of Corticosteroids With COVID-19 Mortality JAMA Network Open. 2022;5:e2234425.
- [24] Dickerman Barbra A., others . Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans New England Journal of Medicine. 2022;386:105–115.
- [25] Hajage David, Combes Alain, Guervilly Christophe, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome Associated with COVID-19: An Emulated Target Trial Analysis American Journal of Respiratory and Critical Care Medicine. 2022;206:281–294.
- [26] Clark Alice J, Salo Paula, Lange Theis, et al. Onset of impaired sleep as a predictor of change in health-related behaviours; analysing observational data as a series of non-randomized pseudotrials International Journal of Epidemiology. 2015;44:1027–1037.
- [27] Rossides Maria, Kullberg Susanna, Di Giuseppe Daniela, et al. Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective 'target trial' emulated with Swedish real-world data *Respirology*. 2021;26:452–460.

- [28] Scola Gianluca, Chis Ster Anca, Bean Daniel, others. Implementation of the trial emulation approach in medical research: a scoping review *BMC Medical Research Methodology*. 2023;23:186.
- [29] Haneuse Sebastien, Daniels Michael. A general framework for considering selection bias in EHRbased studies: what data are observed and why? *eGEMs.* 2016;4.
- [30] O'Brien R., Johnson E., Haneuse S., et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study Annals of Internal Medicine. 2018;169:300-310.
- [31] Tompsett D., Zylbersztejn A., Hardelid P., De Stavola B.. Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness American Journal of Epidemiology. 2023;192:600-611.
- [32] Arterburn D., Courcoulas A.. Bariatric surgery for obesity and metabolic conditions in adults BMJ. 2014;349:g3961.
- [33] Arterburn David E, Johnson Eric, Coleman Karen J, et al. Weight Outcomes of Sleeve Gastrectomy and Gastric Bypass Compared to Nonsurgical Treatment. Annals of Surgery. 2020;274:e1269-e1276.
- [34] Coleman Karen J., Haneuse Sebastien, Johnson Eric, et al. Long-term Microvascular Disease Outcomes in Patients With Type 2 Diabetes After Bariatric Surgery: Evidence for the Legacy Effect of Surgery *Diabetes care*. 2016;39:1400-1407.
- [35] Coleman K. J., Shu Y. H., Fischer H., et al. Bariatric Surgery and Risk of Death in Persons With Chronic Kidney Disease Annals of Surgery. 2022;276:e784–e791.
- [36] Courcoulas Anita P, Christian Nadine J, Belle Steven H, et al. Weight Change and Health Outcomes at 3 Years After Bariatric Surgery Among Individuals with Severe Obesity JAMA. 2013;310:2416–2425.
- [37] Koffman Lily, Levis Alexander W., Arterburn David, et al. Investigating Bias from Missing Data in an Electronic Health Records-Based Study of Weight Loss After Bariatric Surgery Obesity Surgery. 2021;31:2125-2135.
- [38] Koffman Lily, Levis Alexander W., Haneuse Sebastien, et al. Evaluation of Intensive Telephonic Nutritional and Lifestyle Counseling to Enhance Outcomes of Bariatric Surgery *Obesity Surgery*. 2021:1-9.
- [39] Fisher D. P., Johnson E., Haneuse S., et al. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity JAMA. 2018;320:1570–1582.
- [40] Kaiser Permanente . Weight-Loss (Bariatric) Surgery https://healthy.kaiserpermanente.org/healthwellness/health-encyclopedia/he.weight-loss-bariatric-surgery.abq5755 2023.
- [41] Disease Control Centers, Prevention . All About Your A1C https://www.cdc.gov/diabetes/managing/managing-blood-sugar/a1c.html 2023.
- [42] Association American Diabetes. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021 Diabetes Care. 2020;44:S15-S33.

- [43] Hernán M. A., Brumback B., Robins J. M., Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men *Epidemiology (Cambridge, Mass.)*. 2000;11:561–570.
- [44] D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study Statistics in Medicine. 1990;9:1501–1515.
- [45] Robins J. M., Hernán M. A., Brumback B., Marginal Structural Models and Causal Inference in Epidemiology *Epidemiology (Cambridge, Mass.)*. 2000;11:550–560.
- [46] Arterburn David E, Olsen Maren K, Smith Valerie A, et al. Association between bariatric surgery and long-term survival JAMA. 2015;313:62–70.
- [47] Maciejewski Matthew L., Arterburn David E., Van Scoyoc Lynn, et al. Bariatric Surgery and Long-term Durability of Weight Loss JAMA Surgery. 2016;151:1046-1055.
- [48] Hernán Miguel A., Brumback Babette, Robins James M.. Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments Journal of the American Statistical Association. 2001;96:440-448.
- [49] Karim Mohammad Ehsanul, Petkau John, Gustafson Paul, Platt Robert W., Tremlett Helen, BeAMS Study Group. Comparison of Statistical Approaches Dealing with Timedependent Confounding in Drug Effectiveness Studies Statistical methods in medical research. 2018;27:1709–1722.
- [50] Franklin Jessica M, Schneeweiss Sebastian, Polinski Jennifer M, Rassen Jeremy A. Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases *Computational statistics & data analysis*. 2014;72:219–226.
- [51] Li Ron A., Liu Lisa, Arterburn David, et al. Five-year Longitudinal Cohort Study of Reinterventions After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Annals of surgery. 2021;273:758-765.
- [52] Schneeweiss Sebastian, Avorn Jerry. A Review of Uses of Health Care Utilization Databases for Epidemiologic Research Journal of Clinical Epidemiology. 2005;58:323–337.
- [53] Sturmer Til, Schneeweiss Sebastian, Avorn Jerry, Glynn Robert J.. Adjusting Effect Estimates for Unmeasured Confounding with Validation Data Using Propensity Score Calibration American Journal of Epidemiology. 2005;162.
- [54] Sturmer Til, Schneeweiss Sebastian, Rothman Kenneth J., Avorn Jerry, Glynn Robert J.. Performance of Propensity Score Calibration - A Simulation Study American Journal of Epidemiology. 2007;165:1110–1118.
- [55] Toh Sengwee, Rodríguez Luis A. García, Hernán Miguel A. Confounding Adjustment via a Semi-Automated High-Dimensional Propensity Score Algorithm: An Application to Electronic Medical Records *Pharmacoepidemiology and Drug Safety.* 2011;20:849–857.
- [56] Brookhart MA, Rassen Jeremy A, Schneeweiss Sebastian. Instrumental Variable Methods in Comparative Safety and Effectiveness Research *Pharmacoepidemiology and Drug Safety*. 2010;19:537–554.

- [57] Wasserman Larry. All of Statistics: A Concise Course in Statistical Inference. Springer Science & Business Media 2004.
- [58] Efron Bradley, Tibshirani Robert J. An Introduction to the Bootstrap. CRC press 1993.
- [59] Metten Marc-André, Costet Nathalie, Multigner Luc, others. Inverse probability weighting to handle attrition in cohort studies: some guidance and a call for caution BMC Medical Research Methodology. 2022;22:45.
- [60] Thaweethai Tanayott, Arterburn David E., Coleman Karen J., Haneuse Sebastien. Robust Inference When Combining Inverse-Probability Weighting and Multiple Imputation to Address Missing Data with Application to an Electronic Health Records-Based Study of Bariatric Surgery Ann. Appl. Stat. 2021;15:126-147.
- [61] Seaman Shaun R, White Ian R, Copas Andrew J, Li Ling. Combining multiple imputation and inverse-probability weighting *Biometrics*. 2012;68:129–137.
- [62] Breslow N. E., Chatterjee N.. Design and Analysis of Two-Phase Studies with Binary Outcome Applied to Wilms Tumour Prognosis Journal of the Royal Statistical Society. Series C (Applied Statistics). 1999;48:457–468.
- [63] Bang Heejung, Robins James M. Doubly Robust Estimation in Missing Data and Causal Inference Models *Biometrics*. 2005;61:962-973.
- [64] Harrington L. B., Benz L., Haneuse S., others . Bariatric Surgery and the Long-Term Risk of Venous Thromboembolism: A Population-Based Cohort Study Obesity Surgery. 2024;34:2017-2025.
- [65] Levis Alexander. Robust Methods for Causal Inference and Missing Data in Electronic Health Record-Based Comparative Effectiveness Research. PhD thesisHarvard University Graduate School of Arts and SciencesBoston, MA 2022.
- [66] Kennedy Edward H.. Semiparametric doubly robust targeted double machine learning: a review 2023.
- [67] Tsiatis Anastasios. Semiparametric Theory and Missing Data. Springer Series in StatisticsNew York: Springer 2006.

Weight	Purpose	Definition
$W^A_{mk}$	Confounding	$P(A_{mk} \mid L_{mk}, E_{mk} = 1)^{-1}$
$W^C_{mkt}$	Censoring	$\prod_{i=0}^{t} P(C_{mki} = 0 \mid \overline{C}_{mk(i-1)} = 0, \overline{N}_{mk(i-1)} = 0, \boldsymbol{L}_{mki}, E_{mk} = 1, A_{mk})^{-1}$
$W_{mkt}^N$	Non-Adherence	$\prod_{i=0}^{t} P(N_{mki} = 0 \mid \overline{C}_{mk(i-1)} = 0, \overline{N}_{mk(i-1)} = 0, \boldsymbol{L}_{mki}, E_{mk} = 1, A_{mk})^{-1}$
$W^R_{mk}$	Selection Bias	$P(R_{mk} = 1 \mid \bar{A}_{mk}, \bar{L}_{mk}^{c}, C_{mk} = 0)^{-1}$
$SW^A_{mk}$	Confounding	$\frac{P(A_{mk} \mid E_{mk}=1)}{P(A_{mk} \mid \boldsymbol{L}_{mk}, E_{mk}=1)}$
$SW^C_{mkt}$	Censoring	$\frac{\prod_{i=0}^{t} P(C_{mki}=0 \mid \overline{C}_{mk(i-1)}=0, \overline{N}_{mk(i-1)}=0, E_{mk}=1, A_{mk})}{\prod_{i=0}^{t} P(C_{mki}=0 \mid \overline{C}_{mk(i-1)}=0, \overline{N}_{mk(i-1)}=0, L_{mki}, E_{mk}=1, A_{mk})}$
$SW_{mkt}^N$	Non-Adherence	$\frac{\prod_{i=0}^{t} P(N_{mki}=0 \mid \overline{C}_{mk(i-1)}=0, \overline{N}_{mk(i-1)}=0, E_{mk}=1, A_{mk})}{\prod_{i=0}^{t} P(N_{mki}=0 \mid \overline{C}_{mk(i-1)}=0, \overline{N}_{mk(i-1)}=0, L_{mki}, E_{mk}=1, A_{mk})}$
$SW^R_{mk}$	Selection Bias	$\frac{P(R_{mk}=1 \mid \overline{A}_{mk}, C_{mk}=0)}{P(R_{mk}=1 \mid \overline{L}_{mk}^c, \overline{A}_{mk}, C_{mk}=0)}$

 Table 1: Summary of component inverse probability weights

Setting		IPW Me	odels	$egin{array}{c c} {f Mean} \ \hat{\psi}_{PP} & {f Median} \end{array}$		an $\hat{\psi}_{PP}$	
Missingness	$\psi_{PP}$	$oldsymbol{W}^R_{mk}$	$oldsymbol{W}_{mkt}^N$	Bias	% Bias	Bias	% Bias
				-0.021	6.7	-0.023	7.2
		—	$N \sim L^A$	-0.020	6.3	-0.022	6.7
		$R \sim L^{RA}$		-0.012	3.8	-0.009	2.7
			$N \sim L^A$	-0.020	6.2	-0.018	5.7
				-0.010	3.2	-0.016	5.1
M-Bias	-0.322	$R \sim \boldsymbol{L}^{RY}$	$N \sim L^A$	-0.009	2.9	-0.016	5.0
M-Dias	-0.322	D P		0.011	-3.4	0.011	-3.3
		$R \sim L^R$	$N \sim L^A$	0.002	-0.7	0.002	-0.5
		D P A		0.011	-3.4	0.011	-3.3
		$R \sim L^R + A$	$N \sim L^A$	0.002	-0.7	0.000	0.0
	-0.305			0.036	-11.7	0.040	-13.3
			$N \sim L^A$	0.036	-11.7	0.039	-12.9
		$R \sim \boldsymbol{L}^{RA}$		0.035	-11.4	0.034	-11.1
			$N \sim L^A$	0.034	-11.2	0.035	-11.6
		$R \sim L^{RY}$		-0.005	1.7	-0.002	0.6
Treatment Effect			$N \sim L^A$	-0.005	1.7	-0.001	0.4
Heterogeneity				-0.004	1.3	0.003	-1.0
		$R \sim L^R$	$N \sim L^A$	-0.005	1.6	0.003	-1.1
				-0.004	1.3	0.003	-1.1
		$R \sim \boldsymbol{L}^R + A$	$N \sim L^A$	-0.005	1.6	0.003	-1.1
				0.057	-7.0	0.063	-7.7
			$N \sim L^A$	0.057	-6.9	0.062	-7.5
				0.056	-6.8	0.061	-7.4
		$R \sim L^{RA}$	$N \sim L^A$	0.055	-6.7	0.061	-7.5
	or -0.817			-0.001	0.1	0.006	-0.7
M-Bias		$R \sim \boldsymbol{L}^{RY}$	$N \sim L^A$	-0.001	0.1	0.004	-0.5
w/ Mediator				-0.004	0.5	0.005	-0.7
		$R \sim \boldsymbol{L}^R$	$N \sim L^A$	-0.005	0.6	0.004	-0.4
				-0.004	0.5	0.006	-0.7
		$R \sim \boldsymbol{L}^R + A$	$N \sim L^A$	-0.005	0.6	0.004	-0.5

**Table 2:** Simulation results from hypothetical study #1. Eligibility criteria: BMI  $\geq$  35 m/kg<sup>2</sup>, A1c  $\geq$  5.7 %, no previous initiation of bariatric surgery.

Setting		IP	IPW Models			$\mathbf{Mean}\; \boldsymbol{\hat{\psi}}_{PP}$		Median $\hat{\psi}_{PP}$	
Missingness $\psi_{PP}$		Statification $W^R_{mk}$ W		$oldsymbol{W}_{mkt}^N$	Bias	% Bias	Bias	% Bias	
					-0.602	185.3	-0.601	185.0	
				$N \sim L^A$	-0.601	185.0	-0.600	184.4	
					-0.605	186.0	-0.604	185.8	
			$R \sim L^{RA}$	$N \sim L^A$	-0.612	188.3	-0.611	188.0	
					-0.571	175.6	-0.569	175.1	
			$R \sim L^{RY}$	$N \sim L^A$	-0.570	175.3	-0.567	174.4	
		Unstratified			-0.568	174.8	-0.567	174.5	
			$R \sim L^R$	$N \sim L^A$	-0.577	177.4	-0.575	176.7	
					-0.568	174.8	-0.567	174.4	
M-Bias	-0.325		$R \sim L^R + A$	$N \sim L^A$	-0.577	177.4	-0.575	176.7	
111 151005	0.020				-0.602	185.3	-0.603	185.3	
			$R \sim L^{RA}$	$N \sim L^A$	-0.610	187.7	-0.609	187.4	
					-0.006	1.8	-0.005	1.6	
		Stratified by $A$	$R \sim L^{RY}$	$N \sim \boldsymbol{L}^A$	-0.005	1.5	-0.004	1.2	
		Stratified by II			0.001	-0.2	0.002	-0.7	
			$R \sim \boldsymbol{L}^R$	$N \sim \boldsymbol{L}^A$	-0.008	2.4	-0.007	2.1	
					-0.108	35.3	-0.108	35.2	
	-0.307	Unstratified	$R \sim L^{RA}$	$N \sim L^A$	-0.108	35.3	-0.108	35.3	
				$N \sim L^A$	-0.108	35.4	-0.110	36.0	
				$N \sim \boldsymbol{L}^A$	-0.109	35.4	-0.110	35.9	
					-0.141	45.8	-0.141	46.0	
				$N \sim \boldsymbol{L}^A$	-0.140	45.8	-0.143	46.5	
			$R \sim \boldsymbol{L}^R$		-0.140	45.6	-0.145	40.3	
				$N \sim \boldsymbol{L}^A$	-0.140	45.8	-0.141	45.9	
			$R \sim L^R + A$		-0.140	45.6	-0.141	45.4	
Treatment				$N \sim \boldsymbol{L}^A$	-0.140	45.8			
Effect Heterogeneity				$N \sim L$	-0.140	45.8 35.4	-0.141	46.0 35.4	
0 2			$R \sim L^{RA}$	$N \sim L^A$	-0.109			35.2	
				$N \sim L$	0.000	35.5 0.0	-0.108	0.7	
		Cture tiffer 1 have A	$R \sim \boldsymbol{L}^{RY}$	$N \sim \boldsymbol{L}^A$	0.000	0.0	-0.002		
		Stratified by $A$		$N \sim L$	0.000	-0.2	-0.001	0.4	
			$R \sim L^R$	ντΑ					
				$N \sim \boldsymbol{L}^A$	0.000	0.0 2.3	-0.001	0.3	
			_	$N \sim L^A$					
				$N \sim L^{-1}$	-0.016	2.0 2.5	-0.017 -0.019	2.0	
			$R \sim L^{RA}$						
				$N \sim L^A$	-0.018	2.3 9.2	-0.018	2.2	
			$R \sim \boldsymbol{L}^{RY}$		-0.075		-0.074	9.1	
		Unstratified		$N \sim L^A$	-0.073 -0.078	9.0	-0.072	8.9	
M-Bias w/ Mediator			$R \sim \boldsymbol{L}^R$			9.6	-0.078	9.6	
				$N \sim L^A$	-0.076	9.4	-0.076	9.4	
			$R \sim \boldsymbol{L}^R + A$		-0.078	9.6	-0.078	9.6	
	-0.811			$N \sim L^A$	-0.076	9.4	-0.076	9.4	
			$R \sim L^{RA}$		-0.022	2.8	-0.020	2.5	
				$N \sim L^A$	-0.020	2.5	-0.019	2.3	
			$R \sim L^{RY}$		0.001	-0.2	0.003	-0.4	
		Stratified by A	$R \sim L^{RY}$ $R \sim L^R$	$N \sim L^A$	0.003	-0.4	0.005	-0.6	
					-0.002	0.2	-0.001	0.1	
			10.10	$N \sim L^A$	0.000	0.0	0.002	-0.2	

**Table 3:** Simulation results from hypothetical study #2. Eligibility criteria:  $BMI \ge 35 \text{ m/kg}^2$ , no previous initiation of bariatric surgery.

Outcome	Intention-To-Treat $(e^{\hat{\psi}_{ITT}})$	Per-Protocol $(e^{\hat{\psi}_{PP}})$
Any Microvascular Event	$0.438\ (0.382,\ 0.497)$	$0.429 \ (0.375, \ 0.489)$
Nephropathy	$0.340\ (0.239,\ 0.458)$	$0.331 \ (0.236, \ 0.452)$
Neuropathy	$0.436\ (0.367,\ 0.521)$	$0.428\ (0.360,\ 0.512)$
Retinopathy	$0.507 \ (0.400, \ 0.608)$	$0.491 \ (0.394, \ 0.600)$

**Table 4:** Discrete hazard ratio estimates and 95% confidence intervals for the effect of bariatric surgery on microvascular outcomes. Confidence intervals were computed utilizing 1,000 bootstrap replications at the subject (k) level. Eligibility  $(E_{mk})$  was assessed utilizing a 12 month lookback window prior to the start of trial m for blood glucose measures and a 3 month lookback window for BMI measures.

# Supplementary Materials for "Adjusting for Selection Bias Due to Missing Eligibility Criteria in Emulated Target Trials"

Luke Benz<sup>1</sup>, Rajarshi Mukherjee<sup>1</sup>, Issa Dahabreh<sup>1,2,3</sup>, Rui Wang<sup>1,4,5</sup>, David Arterburn<sup>6</sup>, Heidi Fischer<sup>7</sup>, Catherine Lee<sup>8</sup>, Susan Shortreed<sup>9,10</sup>, and Sebastien Haneuse<sup>1</sup>

<sup>1</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>2</sup>CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>3</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>4</sup>Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA

<sup>5</sup>Department of Population Medicine, Harvard Medical School, Boston, MA, USA <sup>6</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

<sup>7</sup>Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA

<sup>8</sup>Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
<sup>9</sup>Biostatistics Division, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

<sup>10</sup>Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA

June 25, 2024

9

### Contents

Aggumptions

STASSUMPTIONS	4
S2 Simulations	3
S2.1 EHR-Based Simulation Infrastructure	3
S2.2 Hypothetical Study Designs	6
S2.3 Analytical Approaches	6
S2.4 Simulation Parameters	7
S3 Data Application	10
S3.1 Estimation of Component Inverse Probability Weights	10
S3.2 Sensitivity of Variance to Eligibility Lookback Times	11
S4 Inference	12
S4.1 Validity of Bootstrap	12
S4.2 Derivation of Asymptotic Variance of $\hat{\psi}_{PP}$	

### S1 Assumptions

Fitting the model in Equation 3 of the main paper estimates the parameter  $\theta$ . Without care,  $\tilde{\theta} \neq \psi$ , the parameter of interest, due to the possibility of selection bias ( $\theta \neq \psi$ ) as well as non-exchangability of treated and untreated subjects due to the possibility of confounding, differential non-adherence, and differential censoring ( $\tilde{\theta} \neq \theta$ ). Recovery of  $\psi$  by fitting the model in Equation 3 with inverse probability weights  $W_{mkt} = W_{mk}^A \times W_{mkt}^C \times W_{mkt}^N \times W_{mk}^R$  requires certain assumptions (1–7). One such assumption is the missing at random (MAR) assumption outlined in Equation 7. Additional assumptions ensure component weights address other potential sources of bias, and guarantee weights are well defined. The complete list of assumptions, as well as some additional commentary, is detailed below.

1. Consistency of outcomes

$$Y_{mkt}^{(\bar{a})} = Y_{mkt} \mid \bar{A}_{mkt} = \bar{a}, E_{mk} = 1$$

2. No unmeasured confounding

$$Y_{mkt}^{(\bar{a})} \perp A_{mkt} \mid \boldsymbol{L}_{mk}, E_{mk} = 1$$

3. Positivity of treatment

$$\epsilon < P(A_{mk} = 1 \mid \boldsymbol{L}_{mk}, E_{mk} = 1) < 1 - \epsilon \text{ for some } \epsilon > 0$$

4. Positivity of remaining uncensored

$$P(C_{mkt} = 0 \mid \bar{C}_{mk(t-1)} = 0, \bar{N}_{mk(t-1)} = 0, \boldsymbol{L}_{mkt}, E_{mk} = 1, A_{mk}) > \epsilon > 0$$

5. Positivity of remaining adherent to baseline treatment

$$P(N_{mkt} = 0 \mid \bar{C}_{mk(t-1)} = 0, \bar{N}_{mk(t-1)} = 0, \boldsymbol{L}_{mkt}, E_{mk} = 1, A_{mk}) > \epsilon > 0$$

6. Conditional independence of censoring and non-adherence

$$N_{mkt} \perp C_{mkt} \mid \bar{N}_{mk(t-1)} = 0, \bar{C}_{mk(t-1)} = 0, L_{mkt}, E_{mk} = 1, A_{mkt}$$

7. Eligibility status missing at random

$$R_{mk} \perp\!\!\!\perp E_{mk} \mid \bar{\boldsymbol{L}}_{mk}^c, \bar{A}_{mk}, C_{mk} = 0$$

#### 8. Positivity of observing eligibility status

$$P(R_{mk} \mid \bar{\boldsymbol{L}}_{mk}^c, \bar{A}_{mk}, C_{mk} = 0) > \epsilon > 0$$

Assumptions 1-3 are standard causal assumptions among eligible patients for addressing confounding via inverse probability weighting (IPW). Assumptions 4-5 are positivity assumptions that ensure inverse probability weights to address non-adherence and censoring are well defined. Assumption 6 facilitates separation of weights to address differential non-adherence and differential censoring with distinct inverse probability weights. We explicitly distinguish censoring due to nonadherence, which is sometimes referred to as artificial censoring (5-13), from censoring due to loss to follow up, development of a competing risk (e.g. death), or other reasons. Artificial censoring due to non-adherence is a direct by-product of underlying treatment mechanisms, making it fundamentally different from other forms of censoring, which are due to distinct mechanisms. While one might choose not to worry about either non-adherence (if intention-to-treat effects are of interest) or canonical censoring (if differential loss to follow up is not a concern), keeping these processes distinct in our notational framework allows for maximal flexibility when addressing these issues. Notably, the two events  $I(N_{mkt} = 0)$  and  $I(C_{mkt} = 0)$  may depend on different variables within  $L_{mkt}$ , or on the same variables to different extents. Modeling weights for each event separately makes it more flexible than modeling the joint even  $I(C_{mkt} = 0, N_{mkt} = 0)$ .

Violations of Assumption 6 seem rare, as violations of such an assumption involve someone being lost to follow-up imminently before non-adhering to their baseline treatment status, or vice versa. In the context of our running bariatric surgery example, such a violation could involve someone disappearing from the electronic health record (EHR) system to receive bariatric surgery at a separate healthcare facility. Under such an an example, the subject would be lost to follow-up at the same time they became non-adherent to their previous non-surgical treatment status. Should such an assumption be exceedingly unrealistic in other settings, analysts may choose not to make this assumption and instead proceed by joint modeling of  $I(C_{mkt} = 0, N_{mkt} = 0)$ .

Assumption 7 is the novel missing at random assumption which allows us to address selection bias via IPW, with associated positively assumption (Assumption 8) ensuring weights are well defined.

### S2 Simulations

#### S2.1 EHR-Based Simulation Infrastructure

First, covariate values  $L_{k0}$  for BMI, A1c, smoking status, comorbidity score, gender, race, and health care site were sampled from observed non-surgical patients in the DURABLE database. Critically, this preserved the joint distribution of these variables from the electronic health records, and thus their complex correlation structure. Next, time-varying BMI and A1c trajectories (and through them, time-varying eligibility status) were simulated in a manner resembling post-surgical patient outcomes (14, 15).

Trajectories in the absence of surgery were simulated as follows:

$$BMI_{kt} = BMI_{k0} \left[ 1 + (\boldsymbol{\beta}_1^T \boldsymbol{L}_{k0} + \gamma_{1k})t + q_k (\boldsymbol{\beta}_2^T \boldsymbol{L}_{k0} + \gamma_{2k})t^2 + \epsilon_{kt}^{(BMI)} \right]$$

$$A1c_{kt} = A1c_{k0} \left[ 1 + (\boldsymbol{\beta}_3^T \boldsymbol{L}_{k0} + \gamma_{3k})t + \epsilon_{kt}^{(AIc)} \right]$$
(S1)

where  $\beta_1, \beta_2, \beta_3$  denote fixed effects,  $\gamma_{1k} \sim N(0, \tau_1^2), \gamma_{2k} \sim N(0, \tau_2^2), \gamma_{3k} \sim N(0, \tau_3^2)$  denote subject specific random,  $q_k$  is a binary indicator of a quadratic BMI trajectory generated from the logistic regression model logit[ $P(q_k = 1 | \mathbf{L}_{k0})$ ] =  $\delta_0 + \delta_1^T \mathbf{L}_{k0}$ , and finally  $\epsilon_{kt}^{(BMI)} \sim N(0, \sigma_{BMI}^2)$  and  $\epsilon_{kt}^{(A1c)} \sim N(0, \sigma^2(A1c_{k0}))$  are random errors. Of particular note, random errors in the generation of BMI trajectories are homoskedastic, while random errors in generation of A1c trajectories are heteroskedastic with variances that are a function of initial A1c values (A1c\_{k0}). The specification in Equation S1 gives us control over the trajectories on the basis of modeling relative weight/A1c change as in previous studies (15–17), with a simple transformation recovering values on the absolute scale.

Next, at each timepoint t, treatment assignments to undergo bariatric surgery were simulated from a logistic regression model,  $\text{logit}[P(A_{kt} = 1 \mid \overline{A}_{k(t-1)} = 0, \boldsymbol{L}_{k0}, \boldsymbol{L}_{kt}, \text{BMI}_{kt} \geq 35 \text{kg/m}^2)] =$ 

 $\alpha_0 + \boldsymbol{\alpha}_1^T \boldsymbol{L}_{k0} + \boldsymbol{\alpha}_2^T \boldsymbol{L}_{kt}$ , where  $\boldsymbol{L}_{kt}$  denotes the current values of any time-varying covariates such as BMI and A1c, and BMI\_{kt} \geq 35 \text{kg/m}^2 indicates that a subject met the treatment eligibility criteria to undergo bariatric surgery (18). An analogous model was used to determine bariatric surgery type, Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG), among those sampled to undergo treatment. Namely, letting  $A'_{kt} = 1$  denote RYGB, bariatric surgery type was assigned via the logistic regression model logit  $[P(A'_{kt} = 1 \mid A_{kt} = 1, \bar{A}_{k(t-1)} = 0, \boldsymbol{L}_{k0}, \boldsymbol{L}_{kt})] = \pi_0 + \pi_1^T \boldsymbol{L}_{k0} + \pi_2^T \boldsymbol{L}_{kt}$ .




Figure S1: Summary of BMI/A1c trajectory generation. Note that for ease of display, trajectories are shown on a relative scale. In simulations however, they exist on an absolute scale. (A) A1c and BMI are first generated in the absence of surgery. (B) Upon assignment to bariatric surgery, subjects are randomized into a latent BMI/A1c class which determines post-surgical mean trajectories. (C) Next, trajectory generation continues post-surgery. (D) Finally, pre- and post-surgical trajectories are combined.

Upon receiving bariatric surgery, the remainder of a subject's BMI and A1c trajectories through the conclusion of follow up (at time  $t = T_{\text{max}}$ ) were generated from a different set of models than non-surgical trajectories. To be specific, let  $\nu_k$  denote treatment time for subject k undergoing surgery, and let  $\eta_k, \xi_k \in \{1, 2, 3, 4, 5\}$  denote latent post-surgical trajectories for BMI and A1c, respectively. Five latent classes were chosen for post-surgical trajectories to match existing literature on heterogeneity of long term weight loss outcomes following bariatric surgery (15). In our simulations, latent post-surgical classes were sampled for subjects undergoing bariatric surgery from the ordinal logistic regression models:

$$logit[P(\eta_{k} \leq j) \mid A_{k\nu_{k}} = 1, A'_{k\nu_{k}}, \boldsymbol{L}_{k0}, \boldsymbol{L}_{k1})] = \lambda_{0j} + \boldsymbol{\lambda}_{1}^{T} \boldsymbol{L}_{k0} + \boldsymbol{\lambda}_{2}^{T} \boldsymbol{L}_{k\nu_{k}} + \lambda_{3} A'_{k\nu_{k}}$$

$$logit[P(\xi_{k} \leq j) \mid A_{k\nu_{k}} = 1, A'_{k\nu_{k}}, \boldsymbol{L}_{k0}, \boldsymbol{L}_{k1})] = \phi_{0j} + \phi_{1}^{T} \boldsymbol{L}_{k0} + \phi_{2}^{T} \boldsymbol{L}_{k\nu_{k}} + \phi_{3} A'_{k\nu_{k}}$$
(S2)

For time  $t \in (\nu_k, T_{\text{max}}]$ , post-surgical trajectories were generated as follows:

$$BMI_{kt} = BMI_{k\nu_k} \left[ 1 + \sum_{j=1}^5 I(\eta_k = j)b(t - \nu_k)^T (\beta_j^{(BMI)} + \gamma_{4k}) + \epsilon_{kt}^{(BMI)} \right]$$

$$A1c_{kt} = A1c_{k\nu_k} \left[ 1 + \sum_{j=1}^5 I(\xi_k = j)b(t - \nu_k)^T (\beta_j^{(A1c)} + \gamma_{5k}) + \epsilon_{kt}^{(A1c)} \right]$$
(S3)

where  $b(t)^T$  denotes a natural cubic spline on time, with coefficients  $\beta_j^{(BMI)}$  and  $\beta_j^{(A1c)}$  corresponding to latent class j. Specific values for  $\beta_j^{(BMI)}$  and  $\beta_j^{(A1c)}$  were choosen based on a combination of empirical fits in the DURABLE database and prior work on long term outcomes following bariatric surgery, in particular work by Arterburn et al. (16) and Courcoulas and colleagues (15). In Equation S3,  $\gamma_{4k} \sim N(0, \tau_4^2)$  and  $\gamma_{5k} \sim N(0, \tau_5^2)$  denote subject-specific random effects. A graphical overview of BMI and A1c trajectory generation is outlined in Figure S1.

Outcomes, in the form of monthly binary indicators of an event were generated from the logistic regression model logit  $[P(Y_{kt} = 1 \mid A_{kt}, \mathbf{L}_{k0}, \mathbf{L}_{kt})] = \omega_0 + \omega_1^T \mathbf{L}_{k0} + \omega_2^T \mathbf{L}_{kt}$  for  $t \in [0, \min(T_k^*, T_{\max})]$ . Finally, complete case indicators of eligibility ascertainment were sampled from the logistic regression model logit  $[P(R_{kt} = 1 \mid A_{kt}, \mathbf{L}_{k0}, \mathbf{L}_{kt})] = \rho_0 + \rho_1^T \mathbf{L}_{k0} + \rho_2^T \mathbf{L}_{kt}$ . In time periods where  $R_{kt} = 0$  values of BMI<sub>kt</sub> and A1c<sub>kt</sub> were set to be missing.

While this simulation infrastructure has many moving pieces and seems highly complex, such complexity helps adequately characterize and understand the problem of missing eligibility criteria in the context of EHR-based observational studies. Figure S2 provides an overview of the EHR-based simulation infrastructure developed as part of this work. Specific covariates used in each model, as well as exact coefficient values are outlined in Section S2.4.




Figure S2: Overview of simulation infrastructure. First, a set of time-invariant covariates are sampled from observed non-surgical patients in the DURABLE database. Next, BMI and A1c trajectories are generated in the absence of surgery, until either the end of study or assignment to undergo surgery, at which point post-surgical trajectories are sampled (Figure S1). Finally, outcomes and eligibility ascertainment indicators are sampled for each time, and eligible status ( $E_{kt}$ ) and associated eligibility defining covariates  $L_{kt}^e$  are set to be missing, at which point application of analytical methods proceeds.

#### S2.2 Hypothetical Study Designs

In the first hypothetical study, eligibility criteria for trial m required a BMI measurement exceeding  $35 \text{ kg/m}^2$  and an A1c measurement of at least 5.7% within the first time period of the trial, and that subjects had not previously undergone bariatric surgery, thereby restricting the study population to those who were simultaneously pre-diabetic and eligible for consideration to undergo bariatric surgery at the start of the trial. Under this scenario, eligibility ascertainment is a problem equally affecting both study arms. Undergoing surgery implies a patient must have met the clinical recommendation for BMI of at least 35 kg/m<sup>2</sup> at the time of surgery, and hence we are able to conclude that they meet the study BMI criteria, even if no BMI measurement was available at the time of surgery. However, due to the additional A1c threshold in the eligibility criteria, knowing a patient underwent surgery and met the specific BMI eligibility criterion says nothing about their A1c, and thus their study eligibility can not be deduced at that point in time.

In the second hypothetical study, the only eligibility criterion consisted of having a BMI above  $35 \text{ kg/m}^2$  during the initial time period of trial m, and not having previously undergone bariatric surgery. By the argument in the previous paragraph, the inability to ascertain eligibility is a one sided problem affecting only non-surgical patients. Note that the implication that undergoing treatment makes one eligible for an observational study will only be true when the requisite criteria for treatment initiation (should any exist) are identical to the eligibility criteria of the corresponding observational study. For example, had a emulated trial been interested in a different population of more severely obese patients, and required a BMI of 40 kg/m<sup>2</sup>, a cutoff different than the clinical minimum of  $35 \text{ kg/m}^2$  in the Kaiser system, treatment initiation would not directly imply eligibility for the corresponding observational study.

In practice, it is often the case that eligibility for initiation of a treatment may be the same as, or at least a subset of eligibility for an observational study, especially if the observation is comparing the effectiveness of treatment vs. no treatment. In such settings, in order to make rigorous comparisons between initiators and non-initiators, analysis is restricted to those who underwent initiation of a treatment and those who were hypothetically eligible for initiation but did not undergo treatment.

In both hypothetical studies considered,  $\mathbf{L}^{RA} = (\text{Smoking Status}, \text{Health Care Site})$  and  $\mathbf{L}^{RY} = (\text{Comorbidity Score})$  when missing data were generated the mechanisms outlined in Figures 3a and 3b. When missing data were generated in a manner outlined in Figure 3c,  $\mathbf{L}^{RA} = (\text{Health Care Site})$  and  $\mathbf{L}^{RY} = (\text{Comorbidity Score}, \text{Insulin Usage})$ . In the context of these simulations, mediators  $\mathbf{M}$  are BMI and A1c values, whose respective observation frequency vary in practice. In all cases, smoking status was the only covariate which influenced the probability to undergo bariatric surgery ( $\mathbf{L}^A$ ) with health care site influencing the type of bariatric surgery a subject underwent.

#### S2.3 Analytical Approaches

In total, 1000 simulated datasets were generated for each combination of study question and missing data mechanism. Each dataset consisted of K = 10,000 subjects followed over a period of  $T_{\text{max}} = 36$  months. Data were analyzed using a sequential target trial emulation framework with trials in each of the first 12 months. M = 12 was chosen to keep the final analysis dataset at a reasonable size. M

In the extreme where all K subjects are eligible for all M trials, and there isn't censoring/nonadherence/incidence of the outcome, which would remove certain observations from the final analysis dataset, the size of the pooled analysis data set is  $T_{\max}$  is  $K \sum_{m=1}^{M} (T_{\max} - m + 1) = KM(T_{\max} - \frac{M+1}{2})$ observations. While of course eligibility/censoring/non-adherence/incidence of the outcome will all reduce the size of the final analysis dataset, choosing M = 12 instead of the theoretical maximum of  $M = T_{\max}$  reduces the size of a single simulated dataset by tens or even hundreds of thousands of observations. More importantly, however, choosing  $M < T_{\max}$  is necessary to allow sufficient follow up time for subjects in later trials. In our data application, the last trial was started such that nearly 5 years of follow-up were possible.

In order to understand finite sample properties of various estimators of  $\psi_{PP}$ , we computed the model in Equation (6) with different combinations of (stabilized) weights  $SW_{mk}^R$  and  $SW_{mkt}^N$ . Confounding was not considered in simulations, as the use of inverse probability weights to address confounding is well understood. For analogous reasons, differential right-censoring (e.g. due to loss to follow-up) was not considered. Thus, weights for confounding  $(SW_{mk}^A)$  and differential censoring  $(SW_{mkt}^C)$  were not required for analysis.

In the hypothetical study design with eligibility criteria comprised only of a BMI measurement of  $35 \text{ kg/m}^2$  or greater, we considered missing data weights stratified by treatment status. Due to the the fact that eligibility for inclusion in this hypothetical study (at the time of treatment initiation) was guaranteed by electing to undergo bariatric surgery,  $P(R_{mk} \mid A_{mk} = 1) = 1$  and thus so should weights  $W_{mk}^R$ . To understand performance of the estimator from Equation (6) under different weight specifications, we computed various combinations of weights both (correctly) stratified by treatment status and unstratifed.

Under our simulations, we considered bariatric surgery as a non-reversible treatment, and thus someone initiating treatment is by definition always adherent to their baseline treatment status during the trial in which they enter as a surgical initiator. As such, non-adherence weights were only estimated for subjects entering each trial m as non-initiators of surgery, that is eligible subjects for whom  $A_{mk} = 0$ , with weights  $W_{mkt}^N = 1$  for all initiators of surgery. Fitting separate models for non-adherence stratified by treatment status has been considered in existing target trial emulations (4, 5, 8, 19, 20), especially in the context of one sided non-adherence (9, 10).

True values of  $\psi_{PP}$  in each setting were computed by fitting Equation (6) before missing eligibility criteria was imposed, with inverse probability weights for non-adherence from correctly specified models, and averaging the results across the 1000 simulated datasets. The true value of  $\psi_{PP}$  was computed in this manner due to the complex nature through which outcomes were generated, which involved a series of high dimensional, non-linear, conditional models. As such, no closed form for the marginal parameter of interest was readily attainable.

#### S2.4 Simulation Parameters

Spline coefficients for post-surgical BMI and A1c trajectories, as displayed in Figure 4, are shown in Table S1. Coefficient values used in simulation studies are available in Table S2.

Measure	$oldsymbol{eta}_1$	$oldsymbol{eta}_2$	$\beta_3$	$oldsymbol{eta}_4$	$oldsymbol{eta}_5$
	-0.181	-0.186	-0.191	-0.196	-0.201
	-0.205	-0.221	-0.232	-0.245	-0.256
	-0.198	-0.225	-0.243	-0.263	-0.281
	-0.178	-0.216	-0.240	-0.268	-0.292
	-0.154	-0.204	-0.234	-0.269	-0.300
	-0.125	-0.175	-0.225	-0.268	-0.305
BMI	-0.111	-0.161	-0.211	-0.261	-0.305
	-0.096	-0.140	-0.184	-0.241	-0.292
	-0.047	-0.085	-0.122	-0.187	-0.244
	-0.207	-0.238	-0.269	-0.342	-0.405
	0.003	-0.022	-0.047	-0.127	-0.197
	-0.110	-0.115	-0.120	-0.125	-0.130
	-0.093	-0.104	-0.117	-0.129	-0.141
	-0.067	-0.084	-0.105	-0.124	-0.143
A1c	-0.008	-0.031	-0.060	-0.086	-0.112
	-0.130	-0.159	-0.196	-0.229	-0.262
	0.024	-0.011	-0.056	-0.096	-0.136

**Table S1:** Spline coefficients  $\beta_j$  for post-surgical BMI and A1c trajectories. A subject's set of coefficients are determined by latent post-surgical classes  $\eta_k$  (for BMI) and  $\xi_k$  (for A1c). Knots for BMI splines are at t = 3, 6, 9, 12, 15, 18, 21, 24, 36, and 48 months, while knots for A1c splines are at 3, 9, 15, 30 and 48 months.

Ν	Iodel Informat	tion	Missi	ngness Mecha	anism
Component Model	Coefficient	Variable	Fig. 3a	Fig. 3b	Fig. 3c
		(Intercept)	$-5 \times 10^{-4}$	$-5 \times 10^{-4}$	$-5 \times 10^{-4}$
		gender	0	0	$-1 \times 10^{-4}$
	$\beta_1$	race	0	0	$-2 \times 10^{-4}$
		insulin	0	0	$5 \times 10^{-4}$
		(Intercept)	0	0	0
	$\beta_2$	insulin	0	0	$1 \times 10^{-5}$
		(Intercept)	-1.10	-1.10	-1.10
Pre-Surgery BMI	δ	insulin	0	0	0.50
Tre-Surgery Dim	$\sigma^2_{\rm BMI}$		$3.2 \times 10^{-3}$	$3.2 \times 10^{-3}$	$3.2 \times 10^{-3}$
	$\tau_1^2$		$5 \times 10^{-4}$	$5 \times 10^{-4}$	$5 \times 10^{-4}$
	$ au_2^2$		$2 \times 10^{-5}$	$2 \times 10^{-5}$	$2 \times 10^{-5}$
		(Intercept)	0	0	0
	$\beta_3$	insulin	0	0	$-1 \times 10^{-3}$
Pre-Surgery A1c	$\sigma^2_{A1c}$	I(hgba1c^2)	$1 \times 10^{-3}$	$1 \times 10^{-3}$	$1 \times 10^{-3}$
	$\tau_2^3$		$3 \times 10^{-4}$	$3 \times 10^{-4}$	$3 \times 10^{-4}$
		(Intercept)	-3.18	-3.18	-3.18
	α	smoking_status[current]	-2.00	-2.00	-2.00
	L L	smoking_status[former]	-0.75	-0.75	-0.75
Treatment		(Intercept)	0.41	0.41	0.41
	π	site	0.69	0.69	0.69
	$\lambda_{01}$	(Intercept)	-2.94	-2.94	-2.94
	$\lambda_{02}$	(Intercept)	-1.10	-1.10	-1.10
	$\lambda_{03}$	(Intercept)	1.10	1.10	1.10
	$\lambda_{04}$	(Intercept)	2.94	2.94	2.94
		elix_score	0	0	-5.00
Post-Surgery BMI		bs_type[rygb]	0	0	4.00
	$\lambda_1$	insulin	0	0	-3.00
	$\tau_4^2$		$2.5 \times 10^{-2}$	$2.5 \times 10^{-2}$	$2.5 \times 10^{-2}$
	\$\phi_{01}\$	(Intercept)	-2.94	-2.94	-1.39
	\$\phi_{02}\$	(Intercept)	-1.10	-1.10	-0.20
	\$\phi_{03}\$	(Intercept)	1.10	1.10	1.73
	\$\$\phi_{04}\$\$	(Intercept)	2.94	2.94	2.94
		elix_score	0	0	-5.00
Post-Surgery A1c		bs_type[rygb]	0	0	4.00
	$\phi_1$	insulin	0	0	-3.00
	$\tau_5^2$		$2.5 \times 10^{-2}$	$2.5 \times 10^{-2}$	$2.5 \times 10^{-2}$
		(Intercept)	-4.18	-3.66	-9.21
		elix_score	1.20	0.25	0
	ω	surgery	-0.36	-0.36	0
Outcome		surgery:elix_score	0	$1 \times 10^{-1}$	0
		bmi	0	0	0.10
		hgba1c	0	0	0.18
		(Intercept)	-2.44	-2.44	-1.10
		elix_score	0.80	0.50	0.60
		site	0.50	0.25	-0.55
Missing Eligibility	ligibility $ ho$	smoking_status[former]	-0.50	-0.50	0
		smoking_status[current]	-1.00	-1.00	0
		insulin	0	0	0.50

Table S2: Coefficients for simulation settings, summarized for each missing data mechanism in Figure 3. Component variables comprising  $L_{k0}$  include gender, race, insulin (usage), smoking\_status and elix\_score (comorbidities). Component variables comprising  $L_{kt}$  include bmi, hgba1c. Treatment variables are denoted by surgery  $(A_{kt})$  and bs\_type  $(A'_{kt})$ 

### S3 Data Application

#### S3.1 Estimation of Component Inverse Probability Weights

In our data application, both intention-to-treat and per-protocol effects were estimated. It's worth pointing out that in this context, non-adherence entailed non-surgical patients in trial m getting surgery at some time t > 0. That is  $A_{mkt} = 1 \neq A_{mk} = 0$  for some t > 0. Non-adherence was one-sided, as one could not undo the treatment of bariatric surgery. In other contexts, adherence might refer to the recommendation to undergo surgery, not the initiation of treatment itself. While intention-to-treat effects under this setting may be of greater clinical interest than ITTs under our setting, we are unable to answer such questions due to lack of data granularity. Nevertheless, we computed both estimands for illustrative purposes.

For the purposes of eligibility ascertainment, and subsequent confounding adjustment,  $L_{mk}^e$  consisted of BMI, blood glucose measures (A1c or fasting blood glucose), and insulin usage/diabetic prescriptions. Critically, these variables could not be used to adjust for the possibility of selection bias. Additional non-eligibility defining covariates,  $L_{mk}^e$ , included sex, health care site, age, race, estimated glucose filtration rate (eGFR), and self-reported smoking status. eGFR was estimated from serum-creatinine values via the CKD-EPI creatinine equation (21). Precise lists of ICD-9 and CPT codes used to define outcomes can be found in the original study by O'Brien et al. (22).

Each component weight model was estimated using a pooled logistic regression model with the following variables:

- Selection bias weights  $(W^R)$ : health care site, baseline age, sex, smoking status, baseline eGFR, surgery
- Confounding weights  $(W^A)$ : health care site, baseline age, sex, smoking status, baseline eGFR, baseline BMI, baseline A1c, baseline insulin usage
- Non-adherence weights  $(W^N)$ : health care site, time-varying age, sex, time-varying smoking status, time-varying eGFR, time-varying BMI, time-varying A1c, baseline insulin usage

Intention-to-treat effects were estimated using weights for confounding and selection bias, while per-protocol effects were estimated with additional weights for non-adherence. No weights were used for censoring, which is implicitly making an assumption of non-informative censoring, as made by O'Brien et al. (22). Time-varying covariates (BMI, A1c, eGRF, age) for non-adherence weights were taken to be the most recent available values.

Weight stabilization was utilized for each component weight according to the formulae in Table 1. Additionally, each component weight was truncated at the 99% quantile, a commonly used threshold in inverse probability weighting (23).

Some subjects were missing baseline eGFR. Since eGFR was not an eligibility defining covariate but nevertheless a useful confounder/covariate for addressing possible selection bias, we imputed it via a Gamma generalized linear model. BMI measurements were not required to determine eligibility for surgical patients ( $A_{mk} = 1$ ) given the unique parallel between study and treatment eligibility. Furthermore, no blood glucose measurement was required for patients with an active diabetes prescription at the start of trial m. For such subjects whose eligibility for the study was partially determined by initiation of bariatric surgery and/or presence of an active diabetic medication prescription, baseline BMI/A1c values (two important confounders) could be missing. Upon restricting to eligible subject-trials, missing BMI/A1c were imputed, again using Gamma generalized linear models. The focus of this work is not missing confounders, another tricky problem which other literature has attempted to address (24–26). Nevertheless, this missingness is worth mentioning because it demonstrates that in real data applications, particularly those in EHR-based observational studies, missing data is likely to be pervasive at many levels of an analysis.

### S3.2 Sensitivity of Variance to Eligibility Lookback Times

Variance estimates for discrete intention-to-treat hazard ratios,  $\exp(\psi_{ITT})$  over the complete grid of lookback times are plotted in Figure S3. Estimates of the variance were derived from B = 100 bootstrap replicates at the subject (k) level (see Section S4 for more details). Due to the size of the data and the number of distinct lookback combinations considered, doing more than 100 replicates per panel, or bootstrapping variance for every per-protocol estimate was not computationally feasible. In general, variance tended to decrease with increasing lookback time, with plateaus mirroring those seen with sample size in Figure 4. Thus, the choice of appropriate lookback windows for determining eligibility can be viewed as a bias-variance trade off. Additionally, as seen in Supplementary Figure S3, inclusion of  $W^R$  for addressing selection bias did not drastically increase variance on top of weights  $W^A$  for confounding for ITT estimates.




Figure S3: Variance of discrete intention-to-treat hazard ratios,  $\exp(\hat{\psi}_{ITT})$ . Variances were estimates from B = 100 bootstrap replicates at the subject (k) level.

### S4 Inference

Inference for the model framework outlined in this work requires care, owing to both the use of inverse probability weights and perhaps more importantly, the fact the the same subject can contribute to multiple trials, including duplicated person-time across these trials. Techniques for estimating the variance of  $\hat{\psi}_{PP}$  (without loss of generality) in the literature can broadly be characterized into two approaches, robust/sandwich standard errors (5, 27, 28) and bootstrapping (4, 8–10, 20, 29–31).

We outline a way to obtain a closed form of the variance of  $\hat{\psi}_{PP}$  in the Section S4.2. In practice, however, such a form would need to be re-derived based on the specific choices for component weight functions. While (pooled) logistic regressions make suitable choices for each weight model, censoring/non-adherence models may be well suited to other forms based on exponential models (32).

As such, we recommend a bootstrapping approach, where replicates are re-sampled at the subject (k) level as opposed to subject-trial or subject-trial-observation level. Though bootstrapping is common in the literature, coverage properties haven't been well studied within this framework. Section S4.1 establishes that this bootstrapping procedure for 95% confidence intervals achieves nominal coverage.

### S4.1 Validity of Bootstrap

In order to establish the validity of re-sampling subjects in order to bootstrap variance and/or confidence intervals, we conducted an additional simulation study. For each of the three missing data scenarios in Figure 3, 1,000 datasets of size K = 5,000 subjects were simulated under the first hypothetical study design outline (with eligibility criteria depending on cutoffs for both BMI and A1c measurements). Note that this is exactly the same simulation set up as hypothetical study #1 with half as many subjects K to make bootstrapping a little bit more computationally feasible.

For each simulated dataset, B = 1,000 bootstrap replications were conducted by re-sampling entire subjects and then running the analysis procedure described in Section S3.1. B = 1,000 is actually a larger number of replicates than are used in much of the literature. For example Hajage and colleagues (10) conducted bootstrapping with B = 200, while Dickerman et al. (30) and Barda and coauthors (31) used B = 500, likely owing to the very large size of the analysis data set.

95% confidence intervals for  $\hat{\psi}_{PP}$  were estimated for each simulated dataset using three different methods: normal intervals, pivotal intervals, and percentile based intervals (33, 34). As seen in Table S3, coverage of 95% confidence intervals roughly achieved nominal rates, confirming that bootstrapping at the subject level is an appropriate inferential procedure in this analytical framework. Due to both discretization of time and pooling of trials, data size typically limits the number of bootstrap replicates which can be conducted in sequential target trial emulations. Given that percentile based methods typically require more replicates to converge, perhaps normal or pivotal intervals are more appropriate.

Setting	Coverage of 95% Confidence Intervals			
Detting	Normal	Pivotal	Percentile	
M-Bias	0.948	0.956	0.944	
Treatment Effect Heterogeneity	0.936	0.935	0.933	
M-Bias w/ Mediator	0.956	0.955	0.948	

**Table S3:** Coverage of 95% confidence intervals from B = 1,000 bootstrap replicates for  $\hat{\psi}_{PP}$  from hypothetical study #1. Bootstrap replicates resample subjects (k) and are computed using 3 different methods.

# S4.2 Derivation of Asymptotic Variance of $\hat{\psi}_{PP}$

For ease of notation, let  $\psi = (\psi_0, \psi_{PP})$  where  $\psi_0$  contains all of the parameters necessary to describe the baseline hazard in the pooled logistic regression of Equation (6). In the absence of missing data, confounding, and any sort of censoring (including due to non-adherence), one could proceed with an analysis based on solving the system of estimating equations

$$U^{C}(\boldsymbol{\psi}) = \frac{1}{K} \sum_{k=1}^{K} U_{k}(\boldsymbol{\psi}) = \frac{1}{K} \sum_{k=1}^{K} \boldsymbol{D}_{k}^{T} \boldsymbol{V}_{k}^{-1}(\boldsymbol{Y}_{k} - \boldsymbol{\mu}_{k}) = \boldsymbol{0}$$
(S4)

where  $\mathbf{Y}_k = (\mathbf{Y}_{1k}, \mathbf{Y}_{2k}, ..., \mathbf{Y}_{mk})$  is the collection of all outcomes a subjects contributes to all trials in the pooled dataset (with analogous notions for  $\mathbf{A}_k, \mathbf{R}_k$  etc.),  $\mu = \mathbb{E}[Y|A] = g_{\mu}^{-1}(\psi_0 + A\psi_{PP})$  where  $g(\cdot)_{\mu}$  is a user-specified link function (e.g. logit link),  $\mathbf{D}_k = \partial \boldsymbol{\mu}_k / \partial \psi$ , and  $\mathbf{V}_k = \text{Var}[\mathbf{Y}_k | \mathbf{A}_k]$ .

Of course, due to the complex observational setting, missing eligibility data, confounding, censoring, and non-adherence all must be addressed, which we choose to do via inverse probability weighting. Assume each set of component weights in a Table 1 is modeled by

$$(W_{mk}^{A})^{-1} = g_{A}^{-1}(\boldsymbol{L}_{mk};\boldsymbol{\alpha}_{A})$$

$$(W_{mkt}^{N})^{-1} = g_{N}^{-1}(\boldsymbol{L}_{mkt};\boldsymbol{\alpha}_{N})$$

$$(W_{mkt}^{C})^{-1} = g_{C}^{-1}(\boldsymbol{L}_{mkt};\boldsymbol{\alpha}_{C})$$

$$(W_{mk}^{R})^{-1} = g_{R}^{-1}(\boldsymbol{L}_{mk}^{c};\boldsymbol{\alpha}_{R})$$
(S5)

where  $g_A(\cdot), g_N(\cdot), g_C(\cdot)$  and  $g_R(\cdot)$  are user specified link functions. Commonly, these may be logit links, enabling a pooled logistic regression approach towards estimating weights, as we do in our simulations. This need not be the case however, as censoring/non-adherence weights may be more appropriately modeled via a Cox model or exponential model (32).

Given consistent estimators for each set of coefficients for modeling weights, say  $\hat{\alpha}_A$ ,  $\hat{\alpha}_N$ ,  $\hat{\alpha}_C$ ,  $\hat{\alpha}_R$ the estimator  $\hat{\psi}$  is then solution to the generalized estimating equation (GEE)

$$U(\boldsymbol{\psi}, \hat{\boldsymbol{\alpha}}_{A}, \hat{\boldsymbol{\alpha}}_{N}, \hat{\boldsymbol{\alpha}}_{C}, \hat{\boldsymbol{\alpha}}_{R}) = \frac{1}{K} \sum_{k=1}^{K} U_{k}(\boldsymbol{\psi}, \hat{\boldsymbol{\alpha}}_{A}, \hat{\boldsymbol{\alpha}}_{N}, \hat{\boldsymbol{\alpha}}_{C}, \hat{\boldsymbol{\alpha}}_{R})$$
$$= \frac{1}{K} \sum_{k=1}^{K} \boldsymbol{D}_{k}^{T} \boldsymbol{V}_{k}^{-1} \boldsymbol{\Delta}_{k}(\hat{\boldsymbol{\alpha}}_{A}, \hat{\boldsymbol{\alpha}}_{N}, \hat{\boldsymbol{\alpha}}_{C}, \hat{\boldsymbol{\alpha}}_{R}) (\boldsymbol{Y}_{k} - \boldsymbol{\mu}_{k})$$
$$= \boldsymbol{0}$$
(S6)

where  $\Delta_k$  is an  $n_k \times n_k$  diagonal matrix with entries  $R_{mk}W_{mkt}$  and  $n_k$  is the total number of rows a subject contributes to the overall pooled dataset (e.g. the length of  $Y_k$ ).

Taking a Taylor series expansion around the true set of parameters  $(\psi^*, \alpha_A^*, \alpha_N^*, \alpha_C^*, \alpha_R^*)$  and multiplying by  $\sqrt{K}$ , we have

$$\begin{aligned} \mathbf{0} &= \frac{1}{\sqrt{K}} \sum_{k=1}^{K} U(\psi^*, \mathbf{\alpha}_A^*, \mathbf{\alpha}_N^*, \mathbf{\alpha}_C^*, \mathbf{\alpha}_R^*) \\ &+ \frac{\partial}{\partial \psi} \mathbb{E}[U_k(\psi, \mathbf{\alpha}_A^*, \mathbf{\alpha}_N^*, \mathbf{\alpha}_C^*, \mathbf{\alpha}_R^*)] \Big|_{\psi = \psi^*} \sqrt{K} (\hat{\psi} - \psi^*) \\ &+ \frac{\partial}{\partial \mathbf{\alpha}_A} \mathbb{E}[U_k(\psi^*, \mathbf{\alpha}_A, \mathbf{\alpha}_N^*, \mathbf{\alpha}_C^*, \mathbf{\alpha}_R^*)] \Big|_{\mathbf{\alpha}_A = \mathbf{\alpha}_A^*} \sqrt{K} (\hat{\alpha}_A - \mathbf{\alpha}_A^*) \\ &+ \frac{\partial}{\partial \mathbf{\alpha}_N} \mathbb{E}[U_k(\psi^*, \mathbf{\alpha}_A^*, \mathbf{\alpha}_N, \mathbf{\alpha}_C^*, \mathbf{\alpha}_R^*)] \Big|_{\mathbf{\alpha}_N = \mathbf{\alpha}_N^*} \sqrt{K} (\hat{\alpha}_N - \mathbf{\alpha}_N^*) \\ &+ \frac{\partial}{\partial \mathbf{\alpha}_C} \mathbb{E}[U_k(\psi^*, \mathbf{\alpha}_A^*, \mathbf{\alpha}_N^*, \mathbf{\alpha}_C, \mathbf{\alpha}_R^*)] \Big|_{\mathbf{\alpha}_C = \mathbf{\alpha}_C^*} \sqrt{K} (\hat{\alpha}_C - \mathbf{\alpha}_C^*) \\ &+ \frac{\partial}{\partial \mathbf{\alpha}_R} \mathbb{E}[U_k(\psi^*, \mathbf{\alpha}_A^*, \mathbf{\alpha}_N^*, \mathbf{\alpha}_C^*, \mathbf{\alpha}_R)] \Big|_{\mathbf{\alpha}_R = \mathbf{\alpha}_R^*} \sqrt{K} (\hat{\alpha}_R - \mathbf{\alpha}_R^*) \\ &+ o_p(1) \end{aligned}$$

Let  $S_k^A(\boldsymbol{\alpha}_A^*)$  be the contribution of the  $k^{th}$  individual to the score for the model used to estimate  $\boldsymbol{\alpha}_A$ , with analogous notions for each set of parameters used in the weight models. We perform similar Taylor series expansions of the estimating equations used to obtain each set of  $\boldsymbol{\alpha}$  parameters and upon rearranging terms, are left with the following expressions.

$$\begin{aligned} \sqrt{K}(\hat{\boldsymbol{\alpha}}_{A} - \boldsymbol{\alpha}_{A}^{*}) &= -\frac{1}{\sqrt{K}} \sum_{k=1}^{K} \left[ \frac{\partial}{\partial \boldsymbol{\alpha}_{A}} \mathbb{E}[S_{k}^{A}(\boldsymbol{\alpha}_{A})] \Big|_{\boldsymbol{\alpha}_{A} = \boldsymbol{\alpha}_{A}^{*}} \right]^{-1} \boldsymbol{R}_{k}^{T} S_{k}^{A}(\boldsymbol{\alpha}_{A}^{*}) \\ \sqrt{K}(\hat{\boldsymbol{\alpha}}_{N} - \boldsymbol{\alpha}_{N}^{*}) &= -\frac{1}{\sqrt{K}} \sum_{k=1}^{K} \left[ \frac{\partial}{\partial \boldsymbol{\alpha}_{N}} \mathbb{E}[S_{k}^{N}(\boldsymbol{\alpha}_{N})] \Big|_{\boldsymbol{\alpha}_{N} = \boldsymbol{\alpha}_{N}^{*}} \right]^{-1} \boldsymbol{R}_{k}^{T} S_{k}^{N}(\boldsymbol{\alpha}_{N}^{*}) \\ \sqrt{K}(\hat{\boldsymbol{\alpha}}_{C} - \boldsymbol{\alpha}_{C}^{*}) &= -\frac{1}{\sqrt{K}} \sum_{k=1}^{K} \left[ \frac{\partial}{\partial \boldsymbol{\alpha}_{C}} \mathbb{E}[S_{k}^{C}(\boldsymbol{\alpha}_{C})] \Big|_{\boldsymbol{\alpha}_{C} = \boldsymbol{\alpha}_{C}^{*}} \right]^{-1} \boldsymbol{R}_{k}^{T} S_{k}^{C}(\boldsymbol{\alpha}_{C}^{*}) \\ \sqrt{K}(\hat{\boldsymbol{\alpha}}_{R} - \boldsymbol{\alpha}_{R}^{*}) &= -\frac{1}{\sqrt{K}} \sum_{k=1}^{K} \left[ \frac{\partial}{\partial \boldsymbol{\alpha}_{R}} \mathbb{E}[S_{k}^{R}(\boldsymbol{\alpha}_{R})] \Big|_{\boldsymbol{\alpha}_{R} = \boldsymbol{\alpha}_{R}^{*}} \right]^{-1} S_{k}^{R}(\boldsymbol{\alpha}_{R}^{*})
\end{aligned}$$
(S8)

Substituting Equation S8 into Equation S7 and rearranging yields

$$\sqrt{K}(\hat{\psi} - \psi^{*}) = -J^{-1} \frac{1}{\sqrt{K}} \left[ \sum_{k=1}^{K} U(\psi^{*}, \alpha_{A}^{*}, \alpha_{N}^{*}, \alpha_{C}^{*}, \alpha_{R}^{*}) - Q_{A}I_{A}^{-1} \sum_{k=1}^{K} \mathbf{R}_{k}^{T}S_{k}^{A}(\alpha_{A}^{*}) - Q_{N}I_{N}^{-1} \sum_{k=1}^{K} \mathbf{R}_{k}^{T}S_{k}^{N}(\alpha_{N}^{*}) - Q_{C}I_{C}^{-1} \sum_{k=1}^{K} \mathbf{R}_{k}^{T}S_{k}^{C}(\alpha_{C}^{*}) - Q_{R}I_{R}^{-1} \sum_{k=1}^{K} S_{k}^{R}(\alpha_{R}^{*}) \right]$$
(S9)

where

$$J = \frac{\partial}{\partial \psi} \mathbb{E}[U_{k}(\psi, \alpha_{A}^{*}, \alpha_{N}^{*}, \alpha_{C}^{*}, \alpha_{R}^{*})]\Big|_{\psi=\psi^{*}}$$

$$Q_{A} = \frac{\partial}{\partial \alpha_{A}} \mathbb{E}[U_{k}(\psi^{*}, \alpha_{A}, \alpha_{N}^{*}, \alpha_{C}^{*}, \alpha_{R}^{*})]\Big|_{\alpha_{A}=\alpha_{A}^{*}}$$

$$Q_{N} = \frac{\partial}{\partial \alpha_{N}} \mathbb{E}[U_{k}(\psi^{*}, \alpha_{A}^{*}, \alpha_{N}, \alpha_{C}^{*}, \alpha_{R}^{*})]\Big|_{\alpha_{N}=\alpha_{N}^{*}}$$

$$Q_{C} = \frac{\partial}{\partial \alpha_{C}} \mathbb{E}[U_{k}(\psi^{*}, \alpha_{A}^{*}, \alpha_{N}^{*}, \alpha_{C}, \alpha_{R}^{*})]\Big|_{\alpha_{C}=\alpha_{C}^{*}}$$

$$Q_{R} = \frac{\partial}{\partial \alpha_{R}} \mathbb{E}[U_{k}(\psi^{*}, \alpha_{A}^{*}, \alpha_{N}^{*}, \alpha_{C}^{*}, \alpha_{R})]\Big|_{\alpha_{R}=\alpha_{R}^{*}}$$

$$I_{A} = \frac{\partial}{\partial \alpha_{A}} \mathbb{E}[S_{k}^{A}(\alpha_{A})]\Big|_{\alpha_{A}=\alpha_{A}^{*}}$$

$$I_{C} = \frac{\partial}{\partial \alpha_{C}} \mathbb{E}[S_{k}^{C}(\alpha_{C})]\Big|_{\alpha_{C}=\alpha_{C}^{*}}$$

$$I_{R} = \frac{\partial}{\partial \alpha_{R}} \mathbb{E}[S_{k}^{R}(\alpha_{R})]\Big|_{\alpha_{R}=\alpha_{R}^{*}}$$

Then, by the a Central Limit theorem argument, we have that

$$\sqrt{K}(\hat{\psi} - \psi^*) \rightarrow \text{Normal}(0, \Omega) 
\Omega = J^{-1}\Gamma J^{-1} 
\Gamma = \text{Var} \left[ U_k(\psi, \alpha_A^*, \alpha_N^*, \alpha_C^*, \alpha_R^*) - Q_A I_A^{-1} S^A(\alpha_A^*) - Q_N I_N^{-1} S^N(\alpha_N^*) - Q_C I_C^{-1} S^C(\alpha_C^*) - Q_R I_R^{-1} S^R(\alpha_R^*) \right]$$
(S11)

### References

- Robins J. M., Hernán M. A., Brumback B., Marginal Structural Models and Causal Inference in Epidemiology *Epidemiology (Cambridge, Mass.)*. 2000;11:550–560.
- Hernán Miguel A., Hernández-Díaz Sonia, Robins James M., A Structural Approach to Selection Bias Epidemiology (Cambridge, Mass.). 2004;15:615–625.
- [3] Hernán MA, Robins J. Causal Inference: What if. Boca Raton: Chapman & Hall/CRC 2024.
- [4] Dickerman Barbra A., García-Albéniz Xabier, Logan Roger W., al. Avoidable Flaws in Observational Analyses: An Application to Statins and Cancer Nature Medicine. 2019;25:1601–1606.
- [5] Danaei Goodarz, Rodríguez Luis A, Cantero Ofelia F, Logan Roger, Hernán Miguel A. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease *Statistical methods in medical research*. 2013;22:70–96.
- [6] Cain Lauren E., Robins James M., Lanoy Emilie, Logan Roger, Costagliola Dominique, Hernán Miguel A.. When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data International Journal of Biostatistics. 2010;6:Article 18.
- [7] Karim Mohammad Ehsanul, Petkau John, Gustafson Paul, Platt Robert W., Tremlett Helen, BeAMS Study Group. Comparison of Statistical Approaches Dealing with Timedependent Confounding in Drug Effectiveness Studies Statistical methods in medical research. 2018;27:1709–1722.
- [8] Emilsson Louise, García-Albéniz Xabier, Logan Roger W, Caniglia Ellen C, Kalager Mette, Hernán Miguel A. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer JAMA Oncology. 2018;4:63–70.
- [9] Maringe Camille, Benitez Majano Sara, Exarchakou Athena, et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data *International Journal of Epidemiology*. 2020;49:1719–1729.
- [10] Hajage David, Combes Alain, Guervilly Christophe, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome Associated with COVID-19: An Emulated Target Trial Analysis American Journal of Respiratory and Critical Care Medicine. 2022;206:281–294.
- [11] Gran Jon Michael, Røysland Kjetil, Wolbers Marcel, et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study *Statistics in Medicine*. 2010;29:2757–2768.
- [12] Petito Lucia C., others . Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)–Medicare Linked Database JAMA Network Open. 2020;3:e200452-e200452.
- [13] Keogh Ruth H, others . Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models *Statistics in medicine*. 2023;42:2191– 2225.

- [14] Arterburn D., Courcoulas A.. Bariatric surgery for obesity and metabolic conditions in adults BMJ. 2014;349:g3961.
- [15] Courcoulas Anita P, Christian Nadine J, Belle Steven H, et al. Weight Change and Health Outcomes at 3 Years After Bariatric Surgery Among Individuals with Severe Obesity JAMA. 2013;310:2416–2425.
- [16] Arterburn David E, Johnson Eric, Coleman Karen J, et al. Weight Outcomes of Sleeve Gastrectomy and Gastric Bypass Compared to Nonsurgical Treatment. Annals of Surgery. 2020;274:e1269-e1276.
- [17] Li Ron A., Liu Lisa, Arterburn David, et al. Five-year Longitudinal Cohort Study of Reinterventions After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Annals of surgery. 2021;273:758-765.
- Kaiser Permanente . Weight-Loss (Bariatric) Surgery https://healthy.kaiserpermanente.org/healthwellness/health-encyclopedia/he.weight-loss-bariatric-surgery.abq5755 2023.
- [19] Massol Julien, Simon-Tillaux Nathalie, Tohme Joelle, et al. Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data *Critical Care.* 2023;27.
- [20] Caniglia Ellen C, Robins James M, Cain Lauren E, others . Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals *Statistics* in Medicine. 2019;38:2428–2446.
- [21] National Kidney Foundatation . CKD-EPI Creatinine Equation https://www.kidney.org/content/ckd-epi-creatinine-equation-2021 2021.
- [22] O'Brien R., Johnson E., Haneuse S., et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study Annals of Internal Medicine. 2018;169:300-310.
- [23] Cole Stephen R, Hernán Miguel A. Constructing inverse probability weights for marginal structural models American Journal of Epidemiology. 2008;168:656–664.
- [24] Levis Alexander. Robust Methods for Causal Inference and Missing Data in Electronic Health Record-Based Comparative Effectiveness Research. PhD thesisHarvard University Graduate School of Arts and SciencesBoston, MA 2022.
- [25] Evans K, Fulcher I, Tchetgen Tchetgen E. A coherent likelihood parametrization for doubly robust estimation of a causal effect with missing confounders arXiv preprint arXiv:2007.10393. 2020.
- [26] Williamson EJ, Forbes A, Wolfe R. Doubly robust estimators of causal exposure effects with missing data in the outcome, exposure or a confounder *Statistics in Medicine*. 2012;31:4382– 4400.
- [27] Gupta Shruti, others . Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 JAMA Internal Medicine. 2021;181:41-51.
- [28] Hernán Miguel, Alonso Alvaro, Logan Roger, et al. Observational Studies Analyzed Like Randomized Experiments An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease *Epidemiology*. 2008;19:766-79.

- [29] Danaei Goodarz, García Rodríguez Luis A, Cantero OF, Logan Roger W, Hernán Miguel A. Electronic medical records can be used to emulate target trials of sustained treatment strategies *Journal of Clinical Epidemiology*. 2018;96:12–22.
- [30] Dickerman Barbra A., others . Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans New England Journal of Medicine. 2022;386:105–115.
- [31] Barda Noam, Dagan Noa, Cohen Cyrille, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study *The Lancet.* 2021;398:2093-2100.
- [32] Peskoe Sarah B, Arterburn David, Coleman Karen J, Herrinton Lisa J, Daniels Michael J, Haneuse Sebastien. Adjusting for selection bias due to missing data in electronic health recordsbased research *Statistical Methods in Medical Research*. 2021;30:2221–2238.
- [33] Wasserman Larry. All of Statistics: A Concise Course in Statistical Inference. Springer Science & Business Media 2004.
- [34] Efron Bradley, Tibshirani Robert J. An Introduction to the Bootstrap. CRC press 1993.